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ABSTRACT 
Distant metastases of solid tumours are the major cause of cancer death. To improve the 
effectiveness of chemotherapy, only marginally active on secondary tumours, anti-metastatic 
agents are needed, i.e. compounds that display the capacity to selectively interfere with 
metastatic formation and growth. Among metal compounds, NAMI-A, 
HIm[Ru(III)Cl4Imdmso], has repeatedly shown a peculiar and selective anti-metastatic 
activity being able to prevent the formation, and to inhibit the growth of established secondary 
tumours. On these bases, the first phase of the project was aimed to investigate how variations 
on the NAMI-A chemical structure can influence the anti-metastatic activity. For this purpose, 
some representative complexes have been chosen: two heterocyclic compounds KP418, 
HIm[Ru(III)Cl4(Im)2], and KP1019, HInd[Ru(III)Cl4(Ind)2], presenting a different N-donor 
ligand, and three organometallic compounds, RM175, [(η6-biphenyl)Ru(II)Cl-
(ethylendiamine)]PF6, its osmium congener AFAP51, [(η6-biphenyl)Os(II)Cl(ethylene-
diamine)]BF4, and RAPTA-T, [RuCl2(η6-toluene)PTA], carrying a PTA ligand instead of 
ethylendiamine. The effects of the compounds on the interference with some steps of the 
metastatic progression are evaluated with appropriate in vitro tests, comparing the behaviour 
of the human MDA-MB-231 highly invasive breast cancer cells to that of human HBL-100 
non tumorigenic mammary epithelial cells. To validate the model, the in vitro effects are 
compared with the in vivo anti-metastatic activity studied in the MCa mammary carcinoma of 
the CBA mouse. The results obtained highlight the selective activity of the organometallic 
compound RAPTA-T towards the highly invasive cell line in vitro, accompanied by a 
selective inhibition of metastasis development in vivo. RAPTA-T seems to act through the 
modulation of tumour cells-extracellular matrix interactions, and of cell motility. In particular 
RAPTA-T induces a cytoskeleton remodelling, mainly through the formation of stress fibres, 
that causes a stiffening of the cell body, particularly evident on MDA-MB-231 cells grown on 
ECM components. These effects, selectively identified in the highly invasive MDA-MB-231 
cells, can be related to the higher ruthenium uptake, detected in this cell line. Cell adhesion, 
migration and invasion are directly related to actin assembly and disassembly, phenomena 
regulated by the RhoGTPases. RAPTA-T completely counteracts the increase of trypsin 
mediated cell detachment induced by the RhoGTPases inhibitor C3 transferase, in MDA-MB-
231 cells grown on fibronectin and collagen IV, and on HBL-100 cells grown on collagen IV. 
These molecular events might stem from the cell surface and involve integrin adhesion 
molecules, as suggested by the role of ECM components in the functional tests and by the 
preference of RAPTA-T to bind them, above all, collagen IV, with which RAPTA-T interacts 
chemically as confirmed by an NMR analysis. The effect of RAPTA-T on cells immediately 
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after the adhesion on the substrate, i.e. mainly adherent with integrinic receptors, suggests that 
RAPTA-T interacts mainly with integrins in the form already bound with the substrate. 
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Abbreviations 
AAS: atomic absorption spectroscopy. 
BSA: bovine serum albumin. 
CMF-DPBS: calcium magnesium free dulbecco’s phosphate buffered saline. 
DMEM: dulbecco’s modified eagle’s medium. 
DMSO: dimethil sulfoxide. 
DPBS: dulbecco’s phosphate buffered saline. 
ECM: extracellular matrix. 
EDTA: ethylenediaminetetra-acetic acid. 
EMT: epithelial-mesenchimal transition. 
FBS: fetal bovine serum. 
HRP: horseradish peroxidise. 
IC50: half maximal inhibitory concentration. 
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Ind: indazole. 
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MMPs: matrix metalloproteinases. 
MTT: thiazolyl blue tetrazolium bromide. 
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PAF: paraformaldeyde. 
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PTA: 1,3,5-triaza-7-phosphoadamantane. 
SDS: sodium dodecyl sulphate. 
SDS-PAGE: sodium dodecyl sulphate polyacrylamide gel electrophoresis. 
SRB: sulforhodamine B. 
TBS: tris buffer saline. 
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TEMED: N,N,N’,N’-tetramethilethil-eneamide. 
Tris Base: trizma base [tris(idrossimetil)aminometano]. 
Tris HCl: trizma base [tris(idrossimetil)aminometano] idrocloruro. 
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1 INTRODUCTION 
1.1 Ruthenium in cancer therapy 
In the last three decades ruthenium compounds have been widely investigated for their 
application as anti-tumour drugs (Kostova, 2006), as an alternative to platinum-based tumour 
inhibitors, that nowadays are the only metal compounds in clinical use for cancer treatment 
(Kelland, 2007). Nevertheless, platinum drugs present some drawbacks like the appearance of 
drug resistances (Brabec and Kasparkova, 2002), the induction of severe side effects, in 
particular Cisplatin is highly toxic (Smith et al, 1991), that limit the dose that can be 
administrated, and the limitation of their spectrum of activity in several oncological diseases 
(Wang et Giandomentico, 1999). Several efforts were done to overcome the limits inherent to 
platinum drugs and to find alternatives. In this optic, the shift from platinum towards 
ruthenium as basic metal of new anti-cancer complexes allows some advantages, like a 
greater number of coordination sites, permitting diverse and numerous geometries, a different 
affinity for the substitution ligands, affecting the rate of the kinetic reactions, and a greater 
number of redox states, that further increases the plethora of possible compounds (Clarke et 
al, 1999). Two main features of ruthenium prompted the researcher’s community to develop 
ruthenium compounds starting from the ’70: the similarity between iron and ruthenium, and 
the relatively lower reactivity of ruthenium(III)- versus ruthenium(II)-compounds. The first 
point deals with the ability of ruthenium to mimic iron in the binding to many biological 
molecules, including serum transferrin, that allows to exploit the greater iron requirement of 
cancer cells, reflected by an increased number of transferrin receptors, to selectively target the 
ruthenium compounds inside tumours (Prongatz et al, 2004; Messori et al, 2000). This 
property suggests to use the relatively inert ruthenium(III) compounds to treat solid tumours, 
where, in an hypoxic and acid environment, they can be “activated” by reduction to the 
corresponding ruthenium(II) compounds, much more reactive towards biological molecules 
(Clarke et al, 1999; Clarke, 2003). These research strategies produced two successful 
ruthenium(III)-compounds: NAMI-A, HIm[Ru(III)Cl4Imdmso], characterized by its selective 
inhibition of metastases from solid tumours (Sava et al, 1998, Bergamo et al, 1999, Sava et al, 
1999; Sava et al, 2003), and KP1019, HInd[Ru(III)Cl4(Ind)2], endowed of an interesting anti-
cancer activity towards autochthonous colorectal tumours (Keppler et al, 1989). NAMI-A, 
first among ruthenium compounds, reached and successfully completed a phase I clinical trial 
(Rademaker-Lakhai et al, 2004) and it is now under evaluation in a phase I/II, promptly 
followed with similar outcome by KP1019 (Hartinger et al, 2006). 
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1.2 Ruthenium heterocyclic complexes 
NAMI-A and KP1019 are both heterocyclic complexes with the metal at the +3 
oxidation state and a pseudo-octahedral geometry, where the four chlorine atoms occupy the 
equatorial positions and the axial ligands are, respectively, one imidazole molecule and one 
dimethysulfoxide in NAMI-A, and two indazole molecules in KP1019. Both compounds can 
incur in hydrolytic processes during which the equatorial leaving groups are substituted by 
water molecules (Lipponer, 2006; Bacac et al, 2004; Sava et al, 2002; Schluga et al, 2006), 
but their similarities are less than it would expect from a first glance. In fact, the presence of 
dimethylsulfoxide in the NAMI-A molecule confers to it a reduction potential much more 
accessible to the hypoxic milieu of solid tumours, than that of KP1019, rendering NAMI-A 
easily reducible to the corresponding ruthenium(II) compound (Alessio et al, 1993; Alessio et 
al, 2004a; Schluga et al, 2006). 
NAMI-A 
 
 
 
 
 
 
 
 
Figure 1.1.Chemical structure of NAMI-A. 
 
The most outstanding activity of NAMI-A (figure 1.1) is its remarkable inhibition of the 
metastases from solid tumours, well documented in several experimental murine tumours and 
in human xenografts (Sava et al, 2003). NAMI-A is able to prevent the development of 
secondary tumours but also to reduce the growth of still established metastases; it is 
noteworthy that these effects are observed without any reduction of primary tumour growth, 
an interesting feature that renders NAMI-A a “true” anti-metastatic drug, potentially able to 
fulfil this unmet need of cancer chemotherapy. 
The in vivo selective effect, only on cells with high metastatic potential, is sustained by 
some activities detected in vitro experiments highlighting the propensity of NAMI-A to 
interfere in the interactions of tumour cells with the extracellular matrix, such as the reduction 
of cell migration and invasion (Sava et al, 2003, Zorzet et al, 2000), the inhibition of the 
gelatinolytic activity of MMP-2 and MMP-9 (Sava et al, 1996; Vacca et al, 2002; Sava et al, 
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2003), the ability to induce rearrangements of the actin cytoskeleton (Sava et al, 2004; Frausin 
et al, 2004). 
Besides these effects on tumour cells, a role in the anti-metastatic action of NAMI-A is 
played by its ability to act as an anti-angiogenic molecule perturbing the NO metabolism, as 
demonstrated in the in vivo models of the rabbit eye (Morbidelli et al, 2003) and of the chick 
chorioallantoinic membrane (Vacca et al, 2002), and in vitro by the inhibition of endothelial 
cell growth and of the Ras-MAPK-ERK pathway (Pintus et al, 2002). 
In phase I clinical study 24 patients were treated at 12 dose levels to determine the 
maximum-tolerated dose, the profile of adverse events and the dose limiting toxicity of 
NAMI-A in patients with solid tumours. The results achieved allows to conclude that NAMI-
A can be administered safely as a 3 hours intravenously (i.v.) at 300 mg/m2/day for 5 days, 
every 3 weeks. Moreover, one patient with pre-treated and progressive non-small cell lung 
cancer had stable disease for 21 weeks (Rademaker-Lakhai et al, 2004). 
KP1019 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.Chemical structure of KP1019. 
 
KP1019, HInd[Ru(III)Cl4(Ind)2] (figure 1.2), emerged as a derivative of KP418, 
HIm[Ru(III)Cl4(Im)2], of which activity against autochthonous colorectal tumours of the rat, 
was significantly ameliorated by the substitution, of the two imidazole molecules in the 
chemical structure of KP418, by two axial indazoles (Keppler et al, 1989). The 
pharmacological interest was justified by the ability of KP1019 to overcome the intrinsic 
cisplatin resistance of the colorectal cancer, and by the activity more pronounced than that of 
5-fluorouracil, at that time the only drug used in the therapy of colorectal tumours (Keppler et 
al, 1989). 
Ru
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The efficacy of KP1019 was demonstrated in vivo in the chemoresistant MAC15A 
colon carcinoma model (Keppler et al, 1993), and in vitro in cell culture studies done with the 
colorectal cell lines SW480 and HT-29, where KP1019 induces apoptosis, predominantly by 
the intrinsic mitochondrial pathway (Kapitza et al, 2005). The apoptotic process is sustained 
by the loss of the mitochondrial membrane potential and by the caspase-dependent cleavage 
of poly-ADP-Ribose-Polymerase (PARP), and it is caused by the generation of reactive 
oxygen species in the colorectal tumour cells, as demonstrated by the reversal of the 
phenomenon by N-acetylcysteine (Kapitza et al, 2005; Kapitza et al, 2005 a). Moreover, in 
the same cell lines KP1019 was found to interact with DNA forming cross-links and inducing 
strand breaks (Frühauf and Zeller, 1991; Malina et al, 2001; Kapitza et al, 2005). 
The in vitro cytotoxic effect of KP1019 is not considerably hampered by drug resistance 
phenomena, forced by the overexpression of the multidrug resistance associated proteins 
MRP1, BCRP, and LRP (Heffeter et al, 2004). On the contrary, P-glycoprotein 
overexpression weakly but significantly (up to 2-fold) reduced KP1019 activity. Acquired 
resistance was investigated by selecting KB-3-1 cells against KP1019 for more than one year. 
Only an approximately 2-fold KP1019 resistance could be induced, and, unexpectedly, it was 
not due to overexpression of P-glycoprotein or other efflux pumps. Accordingly, KP1019 
resistant cells did not display drug accumulation. On these basis, the likeliness of acquiring 
insensitivity to KP1019 during therapy is expected to be low (Hartinger et al, 2006). 
KP1019 was found to react very fast with serum proteins (albumin and transferrin) in 
physiological buffers (Trynda-Lemiesz et al, 2000). The binding to transferrin has important 
implications for the distribution of the compound in live organisms, because it allows the 
entrance in the cells by a transferrin receptors mediated mechanism. Therefore, it seems that 
KP1019 matches one of the principles that drove the research on ruthenium compounds, i.e. 
the trasferrin-mediated transport (Kratz et al, 1994). The binding to albumin suggests, for this 
protein, a role of “long term reservoir” of the drug, confirmed also by the phase I clinical 
study data, stating that the compound is present in the blood stream mainly in a protein bound 
form (Hartinger et al, 2005; Hartinger et al, 2006). During the clinical study none of the 
treated patients experienced serious side effects, while disease stabilization in five of six 
valuable patients was achieved and, in one case, stable disease up to 10 weeks was observed 
(Hartinger et al, 2006). 
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KP418 
 
 
 
 
 
 
 
 
Figure 1.3.Chemical structure of KP418. 
 
The ruthenium compound KP418, HIm[Ru(III)Cl4(Im)2] (figure 1.3), belongs to the 
group of compounds with general formula HB(RuB2Cl4) (B = heterocycle ligands in trans 
position), as is analogue KP1019. In general, KP418 presents an activity similar, although 
weaker in comparison to that of KP1019. 
In vitro studies showed that KP418 has a very low or absent cytotoxicity towards the 
different cell lines tested: colon carcinoma (SW707, SW948 and LoVo), mammary carcinoma 
(MCF-7 and TS/A), and oropharyngeal carcinoma (KB) (Galeano et al, 1992; Zorzet at al 
2000). Despite the low in vitro cytotoxicity, KP418 shows in vivo anti-tumour activity in 
various tumour models, such as the P388 leukemia, the Walker 256 carcinosarcoma (Keppler 
et al, 1987), and the Stockholm Ascitic tumour (Keppler et al 1989), where the ruthenium 
compound is able to increase the survival time of the treated animals. Moreover KP418 
reduces the tumour growth in the sarcoma 180 (Keppler et al, 1987), in the B16 melanoma 
(Keppler et al 1989), and in the Lewis lung carcinoma (Zorzet et al, 2000), but especially in 
the chemically induced colorectal tumours of the rat, where similarly to KP1019, it has an 
activity more pronounced than 5-Fluorouracil (Garzon et al, 1987; Keppler et al 1989). As 
KP1019, also KP418 can bind to trasferrin, although at a slower rate, and with serum 
albumin, significantly altering the structure of the protein (Trynda-Lemiesz et al, 1999; 
Trynda-Lemiesz et al 1999a). 
1.3 Organometallic compounds 
The hypothesis of “activation by reduction” suggests that ruthenium(III) compounds, in 
the hypoxic tumour environment, can undergo activation mediated by the reduction to the 
more reactive ruthenium(II) species (Clarke, 2003). This has led to an increased interest in 
pseudo-octahedral organometallic ruthenium(II) arene complexes, in which the presence of 
the arene stabilizes the metal at the +2 oxidation state. This class of compounds shows an 
N
H
N
N
H
N
Ru
Cl
Cl Cl
Cl
NH
HN
+
-
 14 
half-sandwich “piano –stool” structure (figure 1.4), where the arene is the piano of the stool 
and the ligands, the monodentate leaving group X, and the chelating ligand (YZ), are the legs. 
The carbon-bound and other ligands allow the thermodynamic and kinetic reactivity of the 
metal ion to be controlled and also provide a scaffold for functionalization, so that the design 
can be optimized, both in terms of biological activity and to minimize side-effects. 
 
Figure 1.4. General chemical structure of ruthenium(II) arene “piano-stool” complexes. 
 
The presence of the arene may assist the passage across cell membranes, and it plays a 
role in the mechanism of action of these compounds because it intercalates into DNA causing 
the distortion of the structure (Liu et al, 2006); by increasing the arene hydrophobicity, 
cytotoxicity increases proportionally (Aird et al, 2002). 
The type of leaving group affects the rate of hydrolysis and the cytotoxicity of the 
complex against cancer cells. The highest activity was found for complexes that aquate 
readily (e.g. X = halide), and inactivity for those that do not aquate (e.g- X = pyridine) (Wang 
et al, 2003; Wang et al, 2005). 
Also the nature of the chelating ligand YZ influences the reactivity of the ruthenium(II) 
arene complexes. The rate and the extent of hydrolysis significantly increases if a neutral 
ligand is replaced with an anionic one. Similarly, the nature of the chelating ligand influences 
the rate of binding to DNA nucleobases (Fernández et al, 2004). The overall charge of these 
complexes is determined by the leaving group and the chelating ligand. Positively charged 
molecules probably will be attracted by negatively charged DNA, but a high charge may 
hamper the passage across membranes. For this reason, neutral arene complexes are 
synthesized, which are activated, once inside cells, by the replacement of the negatively 
charged chloride ligand by a neutral water molecule (Yan et al, 2005). 
These Ru(II) arene complexes appear to have an altered profile of biological activity in 
comparison with metal-based anticancer complexes currently in clinical use or in clinical trial 
(Chen et al, 2002; Chen et al, 2003; Liu et al, 2006). 
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RM175 
 
 
 
 
 
 
 
Figure 1.5.Chemical structure of RM175. 
 
Among the organometallic complexes RM175, [(η6-biphenyl)Ru(II)-
Cl(ethylendiamine)]PF6, (figure 1.5) exhibits intriguing in vitro and in vivo activities. 
RM175 in vitro reduces the proliferation of the A2780 ovarian carcinoma (Aird et al, 
2002), 401 NL mammary carcinoma, 529 non-small cell lung carcinoma (Guichard et al, 
2006), HT-29 colon carcinoma, Panc-1 pancreatic carcinoma, NX02 lung carcinoma 
(Habtemariam et al, 2006), showing IC50 values in the micromolar range (1 ÷ 13 µM), so that 
it can be considered equipotent with carboplatin (Aird et al, 2002; Morris et al, 2001). The 
compound does not show cross-resistance in the ovarian A2780 cisplatin resistant cell line. 
On the contrary, a relatively high degree of cross resistance was observed in the same cell line 
resistant to adriamycin, through a mechanism involving the P-glycoprotein that reduces the 
cellular accumulation of the compound (Aird et al, 2002). The in vitro treatment of the 
colorectal cell line HCT116 with RM175 induces apoptosis in a Bax- and p53-dependent way, 
and growth arrest, at both G1 and G2 cell cycle phases, that resulted p53- and p21-dependent, 
while it is independent from Bax (Hayward et al, 2005). 
In the search of the target of RM175, its binding to nucleobases and to DNA is of 
special interest. It is supposed that, after the formation of the aqua species, the ruthenium 
centre could be a potential target for a nucleophilic attack by biomolecules. The investigation 
of the reactions of RM175 with nucleobases shows that it binds preferentially to N7 of 
guanine and that this binding is enhanced by the presence of the ethylendiamine chelating 
ligand (Chen et al, 2003; Wang et al, 2005). RM175 has been found to interact with DNA also 
in cell-free systems, forming stable monofunctional adducts with a kinetic faster than that of 
cisplatin (Novakova et al, 2003). 
The reaction of RM175 with cysteine and methionine was also investigated, because 
sulphur amino acids play important roles in detoxification and drug-resistance mechanisms 
(Wang et al, 2002). The compound reacts slowly with both amino acids: in aqueous solutions, 
at 310 °K and pH = 2 ÷ 6, only 50% of the compound reacts with L-cysteine, and 27% with 
Ru
Cl NH2NH2
PF6-
+
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methionine. Histidine residues are also possible binding sites for RM175, but in this case the 
affinity is even lower than for cysteine and methionine (Wang et al, 2005). From the 
comparison of these studies, amino acids appear to have a low affinity for RM175, thus 
suggesting that, in cells, DNA may be the favoured reaction site for RM175 and similar 
ruthenium compounds (Yan et al, 2005). 
In vivo, the treatment with RM175 significantly delays the growth of  both the ovary 
A2780 carcinoma and of its cisplatin-resistant variant engrafted into the nude mice (Aird et al, 
2002). Similarly to what observed in vitro, RM175 fails to affect the growth of the A2780  
subline resistant to adriamycin. The in vivo anti-tumour activity of RM175 was confirmed 
also in tumour models of lung cancer, like the A549 and the LXFL xenografts (Guichard et al, 
2006). 
AFAP51 
Osmium belongs to the same group  of the periodic table, as iron and ruthenium, and, 
for this reason, it should be able to mimic iron, in the same way of ruthenium. Osmium is the 
heavier congener of ruthenium and it has the reputation of being highly toxic and relatively 
inert in substitution reactions (Peacock et al, 2006); as a consequence it has been little 
investigated for the use in therapeutic agents. In recent years the interest in the chemistry of 
ruthenium(II)-arene complexes, and the numerous investigations in their structure-activity 
relationships, have led to the synthesis of a variety of analogous osmium(II) compounds 
(Peacock et al, 2006; Peacock et al, 2007). 
 
 
 
 
 
 
 
Figure 1.6.Chemical structure of AFAP51. 
 
AFAP51, [(η6-biphenyl)Os(II)Cl(ethylendiamine)]BF4, (figure 1.6) is the congener of 
the ruthenium-arene compound RM175 described above, but respect the parent compound it 
undergoes hydrolysis ca 40 times more slowly (Peacock et al, 2006). This different chemical 
behaviour reflects in the biological properties of the osmium derivative: it is inactive towards 
the A2780 ovarian cancer cells, and also the rate and the extent of the reaction with 
nucleobases, such as 9-ethylguanine, were less than those of RM175 (Peacock et al., 2006). 
Os
Cl NH2NH2
BF4-
+
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Nevertheless, AFAP51 is able to form adducts with DNA, extending four base pair around the 
adduct, that cause distortion and unwinding of plasmidic DNA to a greater extent than that 
observed with the ruthenium analogue, and similar to that induced by several platinum 
compounds (Kostrhunova et al, 2008). 
RAPTAs 
Following the interest boosted by RM175, several other organometallic ruthenium(II) 
compounds have been synthesized and analysed for their biological properties. The RAPTA 
(Ruthenium Arene PTA, PTA = 1,3,5-triaza-7-phosphoadamantane) family of compounds 
with general formula [RuCl2(η6-arene)PTA], was designed on the basis of the RM175 
structure, by substituting the chelating ligand ethylendiamine with the PTA group, in order to 
achieve a selective activation in the low pH milieu of solid tumours. In the hypoxic tumour 
environment the PTA group undergoes protonation, a reaction that activates the PTA ligand 
and favours its interaction with DNA (Allardyce et al, 2001; Allardyce et al, 2003). This 
mechanism is demonstrated for RAPTA-C, [RuCl2(η6-p-cymene)PTA], one of the lead 
compounds of the RAPTAs, able to exhibit pH-dependent DNA damage at the pH typical of 
the hypoxic solid tumour environment, while at the pH typical of healthy cells, little or no 
damage was detected (Allardyce et al, 2001). 
As for most of metal complexes, also for RAPTAs the hydrolytic processes seem to 
play a role in their mechanism of action. The hypothesis is that this class of compounds 
undergoes hydrolysis only inside cells by substitution of chlorides with water molecules, thus 
allowing the compounds to interact with DNA, as demonstrated for RAPTA-C binding to calf 
thymus DNA (Scolaro et al, 2005). 
A study employing an extensive series of RAPTA compounds with modified arene 
ligands showed them to be only poorly cytotoxic towards the murine lung adenocarcinoma 
TS/A cell line, and completely non toxic to the human non tumorigenic HBL-100 cells 
(Scolaro et al,2005; Scolaro et al,2006). In particular, among all the RAPTAs tested in vitro, 
RAPTA-T, [RuCl2(η6-toluene)PTA], emerged for the differential cytotoxic activity in the 
couple, tumour/non-tumour, of used cell lines, showing an IC50 of 74 µM in the TS/A 
adenocarcinoma cells, and being essentially non toxic until 300 µM towards the non 
tumorigenic HBL-100 cells under analogous conditions. The selective cytotoxicity of 
RAPTA-T (figure 1.8) underlines a different behaviour compared to the organometallic arene 
ruthenium(II) compounds  of the class of RM175 described above. 
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Figure 1.8. Chemical structure of RAPTA-T. 
 
The in vivo activity of the RAPTAs was studied for RAPTA-C and RAPTA-B, 
[RuCl2(η6-benzene)PTA], in the MCa mammary carcinoma model, implanted intramuscularly 
in the CBA mouse (Scolaro et al, 2005). A cumulative dose of 400 mg/kg was given applying 
different schedules of administration: 100 mg/kg on days 1, 3, 5, and 7 after tumour implant; 
200 mg/kg on days 5 and 9 after tumour implant; or 400 mg/kg given on day 20 after tumour 
implant. RAPTA-C is able to reduce the number of lung metastases when the total dose of 
400 mg/kg is given fractionated in 2 or 4 treatments. Notably, 200 mg/kg/day, on days 5 and 9 
after tumour implant, appears the most efficient treatment schedule in reducing lung 
metastasis formation. RAPTA-B show similar efficacy with both fractionated treatment 
schedules. Moreover, the growth of the primary tumour is not affected following treatment 
with both RAPTA-C and RAPTA-B (Scolaro et al, 2005). 
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1.4 Antimetastatic therapies: inhibiting metastatic spread without altering the primary 
tumour 
Numerous efforts are addressed at finding drugs acting on targets involved in different 
stages of the metastatic process (Eccles, 2005). In the last years some molecules, which 
correspond to the definition of a specific antimetastatic drug, that should selectively interfere 
with metastasis formation and growth, without altering the growth of the primary tumour have 
been identified. Most of them act by inhibiting different steps of colonization in different 
metastasis models: i. e. RGD (Arg-Gly-Asp) peptidomimetics S137 and S247 (Shannon et al, 
2004); migrastatin, a macrolide-inhibiting rac (Shan et al, 2005), AMG487, an anti-CXCR3 
(Walser et al, 2006); cicaprost, a prostacicline analogue (Schrner et al, 1992); ruthenium 
complexes (Bergamo and Sava, 2007). In particular, NAMI-A was defined as a compound 
acting at multiple levels of the metastatic cascade (Perret and Crépin, 2008) for its ability to 
interfere in detachment (Frausin et al, 2004), migration and invasion processes (Sava et al, 
2003, Zorzet et al, 2000). 
The existence of these molecules, despite their little number, sustains the the possibility 
to find a ‘true’ antimetastatic drug and stimulates to deepen the studies in this direction. The 
features that characterize metastasis in comparison to primary tumour and the research of 
novel targets for the therapy of metastatic disease are largely studied and reviewed (Steeg and 
Theodorescu, 2008; Taylor et al 2008; Eccles and Welch, 2007; Dollé et al, 2006) 
1.5 Genes that regulates metastatic progression 
Metastatic progression can be simplified as a sequence of basic steps that are: 
detachment from primary tumour, local invasion, intravasation, survival in the circulation, 
extravasation and colonization of distant organs(Gupta and Massaguè, 2006). These events 
have been largely studied, and many genetic and epigenetic events that contribute to the 
metastatic path have been identified (Chambers et al, 2002). The metastasis genes are defined, 
more strictly, than those in which gain or loss of function specifically enables tumour cells to 
circulate, home into, penetrate or colonize distant organs (Nguyen and Massaguè, 2007). 
These genes, involved in the different steps of the metastatic progression, can be grouped into 
several classes (Chiang and Massaguè, 2008; Nguyen and Massaguè, 2007), in relation to the 
level they act: 
metastasis initiation genes; 
metastasis progression genes; 
metastasis virulence genes. 
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The borders between initiation genes and progression genes on one hand, and 
progression genes and virulence genes on the other are not well defined (figure 1.9). 
However, it could be a useful division. Moreover, metastasis initiation and progression genes 
are already present at primary tumour level, because they determine some features that are 
necessary for a metastatic cell to escape from the primary tumour or, in some cases, they also 
support tumour growth. The expression in the primary tumours of genes that determine 
metastatic activities are useful in the prediction of prognosis in particular types of cancer 
(Nguyen et al, 2009). 
 
Figure 1.9. Classes of genes participating in the metastatic process.(Nguyen and Massaguè, 2007). These genes 
promote metastasis after opportune transformation of primary tumour. Metastasis genes might act at different 
levels: tumour cells in the primary site (blue cells); metastatic cells (orange cells); cells of the microenvironment 
(light-coloured cells). 
 
Metastasis initiation genes are defined as the genes that are involved in the 
transformations that allow cells to invade the surrounding tissue, to support angiogenesis and 
intravasation, and to attract a supportive stroma. These genes are useful also after that cells 
have infiltrated distant tissues. Among these genes are included several genes involved in 
epithelial-mesenchimal transition (EMT), that is mediated by programmes. These 
programmes are under the control of transcription factors like TWIST, that induces the loss of 
E-cadherin expression. The loss of a protein, like E-chaderin, which mediates cell-cell 
adhesion is strictly related with EMT in epithelial cells (Yang et al, 2004). Another example is 
the loss of function of caspase 8 (CASP8) which favours dissemination, by protecting tumour 
cells from apoptosis upon release of integrin-mediate anchoring at the invasive front (Stupack 
et al, 2006). Among the determinants of invasion there are components and modulators of 
hepatocyte growth factor (HGF)-HGF receptor (HGFR) pathway, such as metaderin that in 
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breast cancer has a dual role in promoting metastatic seeding and enhancing chemoresistance 
(Hu et al, 2009), and the metastatic associated colon cancer 1 (MACC1) gene that promotes 
proliferation, invasion and HGF-induced scattering of colon cancer cells in culture (Stein et 
al, 2009). 
The class of the metastasis progression genes mainly includes genes that allow to relate 
a primary tumour cell to a particular target organ. For example, recent studies suggest that the 
hypoxia regulated gene lysyl oxidase is predictive of relapse in human breast cancer tumours 
(Erler at al, 2006), and the secretion of lysyl oxidase into the lung facilitate the homing of 
disseminated cancer cells into these organs. Among the genes that are expressed in primary 
tumours, but that in same cases do not contribute to primary tumorigenesis, it is interesting to 
take into consideration those that could be part of the response to cytokines. In the tumour 
microenvironment the stromal components, like endothelial cells or bone marrow progenitors, 
release paracrine factors in response to malignancy. Even if some of these signals contributes 
to tumour growth, others are devoid of effects at primary tumour level but are involved in the 
dissemination of cancer cells. An example is C-C chemokine ligand 5 (CCL5), that is released 
by bone marrowderived mesenchymal progenitor cells infiltrating into mammary tumours, 
and stimulates cancer cells to metastatize to the lung without affecting tumorigenesis 
(Karnoub et al, 2007). 
The class of metastases virulence genes is the one that provides a selective advantage in 
secondary sites, but not in the primary tumour. Their altered expression or activity becomes 
discernable in secondary tumours at distant organs, because they do not participate in primary 
tumour development. Moreover these genes accentuate the metastatic tendency of 
disseminated cells that have successfully achieved the previous steps of metastatic initiation 
and progress (Nguyen and Massaguè, 2007). For example, osteoclast-mobilizing factors, such 
as parathyroid hormone related protein (PTHRP) and interleukin 11 (IL11) do not provide an 
advantage to rest cancer cells in primary tumours, but enable them to establish osteoclastic 
metastases in bone. Differently from the two previously described classes of genes, this last 
class of virulence genes do not contribute to the expression signatures that are predictive of 
metastasis in primary tumours (Nguyen et al, 2009). 
1.6 Identification of potential targets in the therapy of metastatic disease 
As described above, the metastatic process is regulated by the activity of specific genes 
that are often distinct from those involved in early oncogenesis. This underline the importance 
of the identification of molecular targets strictly involved in the metastatic spread. For 
example, one of the main features of the metastatic cells is the motile phenotype; some studies 
demonstrated that motile cells are non-proliferating cells (Condeelis et al, 2005), while one of 
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the strategies most followed in cancer chemotherapy is the block the aberrant proliferation of 
tumour cells. For this reason, among the targets identified, as involved in the metastatic 
process, the most interesting are those which control the metastatic spread, and are 
specifically involved in the steps of the metastatic cascade, without interfering with the 
primary tumour growth. The factors leading to the acquisition of the motile phenotype are 
those involved in the epithelial to mesenchimal transition, for example growth factors as 
TGFβ or transcription factors like snail or slug (Kelleher et al, 2006). Metalloproteases and 
Rho proteins play an important role in stroma remodelling that leads directly to intravasation, 
and cytoskeleton reorganization, and are related to cell motility and plasticity. During 
migration and after extravasation the metastatic cells interact with the ECM: in this process 
some membrane proteins like CD44 and integrins have a key role that can facilitate or hinder 
the implantation of the metastatic cell (Mehlen et al, 2006). Moreover cell surface and 
extracellular glycoconjugates play an important role in cell-cell and cell-matrix contact, 
invasiveness, cell survival and differentiation, and it is known that they are modified 
quantitatively and qualitatively during tumour progression (Dube and Bertozzi, 2005). The 
colonization process is preceded by the arrival of myeloid cells from the bone marrow, 
preparing a favourable ‘niche’, for example increasing the secretion of fibronectin (Kaplan et 
al, 2005). Besides, the target organs secrete chemokines which attract the circulating tumour 
cells expressing the cognate receptor. For example it has been demonstrated that the couple 
CXCL12-CXCR4 promotes the dissemination of breast cancer by the blood (Schioppa et al, 
2003). 
All these examples of molecules are potential target for drugs specifically directed 
against secondary lesions. 
1.7 Targets involved in cancer cell motility, invasiveness and adhesion 
Cell motility plays a central role in the tumour invasion and metastasis. This 
phenomenon is strictly related to cell-cell and cell-ECM adhesion and to the dynamic 
organization of the actin cytoskeleton. These features together with the degradation of ECM 
are related with cell invasiveness. Among the molecules involved in these processes integrins 
and RhoGTPases are attracting a great interest. 
Integrins 
Integrins are transmembrane glycoproteins composed of noncovalently linked α and β 
subunits. At least 24 distinct integrins heterodimers are formed by the combination of 18 α-
subunits and 8 β-subunits (figure 1.10) (Hynes, 2002). 
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Figure 1.10. The integrin receptor family (Hynes, 2002). In figure are represented the association among the 
mammalian subunits.  
 
Integrins are essential for cell migration and invasion because they mediate adhesion of 
cells to the ECM, and regulate intracellular signalling pathways that control cytoskeleton 
organization, force generation and survival. The repertoire of integrins present on a cell 
dictates the extent to which that cell will adhere to, and migrate on different matrices. This 
happens because integrins recognize specific sequences on their ligands. One of the first 
studies identified αv and α5β1 integrin receptors that recognize the RGD sequence (Pytela et 
al, 1985). Once ligated with ECM, integrins form structures known as focal adhesion, recruit 
and activate kinases, such as focal adhesion kinases (FAKs) and Src family kinases (SFKs) 
(Berrier and Yamada, 2007). Moreover integrins couple ECM to the actin cytoskeleton by 
recruiting proteins like talin, viniculin, paxillin, α-actinin and tensin. Integrins also activate 
small GTPases (figure 1.11), which in turn activate downstream effectors molecules, leading 
to rearrangement of actin stress fibres and activation of cell adhesion and spreading 
(Salsmann et al, 2005).  
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Figure 1.11. Schematic representation of integrin signalling and focal adhesion components (Avraamides et al, 
2008). 
 
Integrins expressed in tumour cells regulate different functions that contribute to the 
processes of migration, invasion and survival, related to the metastasis process. This makes 
integrins interesting as therapeutic targets and also as biomarkers (Desgrosellier and Cheresh, 
2010). In fact integrin expression can vary considerably between normal and tumour tissue. 
For example integrins α5β1, αvβ3, and αvβ6 are usually expressed at low levels in most adult 
epithelia but can be upregulated in some tumours (Takayama et al, 2005; Felding-Habermann 
at al, 2001; Adachi et al, 2000; Bates et al, 2005). On the other side, it is known that α2β1 
decreases in tumour cells and this favours tumour cell dissemination (Kren et al, 2007). It has 
been demonstrated that a re-expression of α2β1 in breast cancer cells reversed some of the 
malignant properties of  those cells (Zutter et al, 1995). 
Integrins also contribute to tumour cell invasion by regulating the localization and 
activity of matrix-degrading proteases, such as matrix metalloprotease 2 (MMP2) and 
urokinase-type plasminogen activator (uPA) (Maupas-Schwalm et al, 2009). The regulation of 
integrin recycling is also crucial for tumour cell invasion. RabGTPases direct integrins to the 
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leading edge of invading tumour cells (Caswell et al, 2008) and co-ordinately regulate 
integrin and growth factor signalling. 
RhoGTPases 
The Rho Family of GTP-binding proteins, which include Rho (A, B, C), Rac (1, 2, 3) 
and Cdc42, are central players in the regulation of the dynamic organization of the actin 
cytoskeleton, that provides the force for cell motility (Jaffe and Hall, 2005). Rho, including 
RhoA, RhoB, and RhoC, controls actin stress fibres and focal contact formation, whereas Rac 
and Cdc42 are responsible for the formation of lamellipodia and filopodia respectively (figure 
1.12).  
 
 
Figure 1.12. Signal-transduction pathways involved in: Rho induced stress fibres assemblay; Rac and Cdc42 
formation of actin containing lamellipodia and filopodia respectively (Bishop and Hall, 2000). 
 
Most Rho family members act as molecular switches, cycling between a GTP-bound 
active form and a GDP-bound inactive form (Figure). Their activity is increased by guanine 
nucleotide exchange factors (GEFs) which promote the release of GDP and subsequent 
binding of the more abundant GTP, and downregulated by GTPase-activating proteins 
(GAPs), which stimulate the hydrolysis of GTP (Bos et al, 2007) (figure 1.13). Rho proteins 
are post-traslationally modified at the C-terminus with the addition of a lipidic group by 
prenylation or palmitoylation, thereby enhancing their interaction with membranes. GDI 
proteins (guanine-nucleotide-dissociation inhibitors) regulate the activity of Rho GTPases by 
binding to the C-terminal prenyl group, preventing their membrane association and 
sequestering them in the cytoplasm, and thus frequently inhibiting their access to downstream 
targets (Dovas and Couchman, 2005). 
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Figure 1.13. RhoGTPases, the cycle between an active (GTP-bound) and an inactive (GDP-bound) 
conformation (Etienne-Manneville and Hall, 2002). 
 
RhoGTPases have been reported to contribute to most steps of cancer initiation and 
progression like survival, evasion from apoptosis, tissue invasion and metastasis (Vega and 
Ridley, 2008). 
Among the Rho subfamily, RhoA and RhoC expression is found frequently increased in 
human tumours, while RhoB is often down regulated (Gomez et al, 2005). These proteins are 
of particular interest as therapeutic targets because they are involved in all the modes of 
cancer cell motility: mesenchimal, ameboid and collective (figure 1.14). RhoA-ROCK 
signalling is proposed to induce actomyosin-based cortical contractility, leading to ameboid 
migration via blebbing, as well as tail retraction in mesenchimal migration (Friedl and Wolf, 
2003). RhoGTPases can also regulate the production of MMPs, affecting matrix remodelling 
and tumour cell invasion (Lozano et al, 2003). 
Noteworthy is the involvement of RhoC in cancer progression that seems strictly related 
with metastasis (Hakem at al, 2005). Increased RhoC expression has been claimed as the 
possible cause for the induction of invasion and metastasis in breast cancer (Ma et al, 2007). 
On the contrary, the expression of RhoB in human tumours is inversely correlated with 
tumour aggressiveness (Huang and Prendergast, 2006). Probably RhoB acts as a tumour 
suppressor, it is activated in response to several stimuli, including DNA damage or hypoxia, 
and it inhibits tumour growth, cell migration and invasion.  
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Figure 1.14. Tumour invasions mechanisms. Different migration strategies are determined by different 
molecular programmes (triangles). Individual movements (ameboid and mesenchimal) are mainly controlled by 
integrins and matrix-degrading proteases. Collective cell movements are regulated by cadherins and gap 
junctions (Friedl and Wolf, 2003). 
 
1.8 Drugs acting on cancer cell motility, invasiveness, and adhesion 
Cancer cells disseminate from the primary tumour either as individual cells, using 
ameboid- or mesenchimal-type movement, or as cell sheets, strands and clusters using 
collective migration (Friedl and Wolf, 2003) (figure 1.14). As described above, among all the 
proteins involved in the regulation of motility, Rho proteins are an interesting class of small G 
proteins involved in all the migratory models. Rho GTPases, and their effectors (ROCK, p21 
activated kinase (PAK)) are involved in numerous aspects of the metastatic cascade (cell 
adhesion, motility, invasion), for this reason they are interesting targets for the development 
of anti-metastatic drugs (Aznar et al, 2004). So far ROCK inhibitors, like Y-27632 (Takamura 
et al, 2001), and two ATP antagonists (CEP1347, KTD606) that inhibit PAK (Nheu et al, 
2002) have been synthesized. Moreover, migrastatin a macrolide extracted from streptomyces, 
inhibits rac activation and consequently the migration of cancer cell (Shan et al, 2005). A 
series of studies developed on statins and bisphosphonates, drugs that inhibit the mevalonate 
pathway and the prenylation necessary for the activation of small G proteins is noteworthy 
(Andela et al, 2003). This studies have shown inhibitory effects on cancer cell motility in 
vitro, and in vivo antimetastatic activity has been recognized (Taras et al, 2007; Soltau et al, 
2004).  
Cell migration rely on the generation of adhesive forces at the rear of the migrating cell 
(Schwartz and Horwitz, 2006), a phenomenon where integrins, focal adhesion kinase and 
RhoA are implicated. Particular interest is addressed to the creation of anti-adhesive drugs 
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targeting integrins and their ECM substrates (collagens, fibronectin…). Among the integrin 
inhibitors that affect cell adhesion, the most studied are pseudopeptides or non-peptide drugs 
mimicking the RGD sequence of the natural substrates (Shannon et al, 2004). S137 and S247 
are two low molecular-weight peptidomimetics of the ligand amino acid sequence arg-gly-asp 
(RGD). These two molecules are potent integrin antagonists, able to reduce cell migration in 
vitro and to inhibit metastasis through multiple mechanisms, without interfering with primary 
tumour growth in vivo. Another interesting molecule is Salvicine, a novel diterpenoid quinine 
compound, that significantly reduces the metastatic potential of MDA-MB-435 cells without 
affecting the growth of the primary tumour (Lang et al, 2005; Zhou et al, 2008). Additionally 
to the in vivo activity, Salvicine possesses also the capability to decrease cellular migration 
and adhesion in vitro. These properties are related to the inactivation of β1 integrin and the 
inhibition of the translocation of RhoA and RhoC from the cytosol to the cellular membrane 
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2 AIM OF THE STUDY 
The ruthenium complex NAMI-A has been defined as a drug acting at multiple levels of 
the metastatic cascade (Perret and Crépin, 2008). Its anti-metastatic properties could be 
related with the capability to inhibit some steps of the metastatic progression; nevertheless, its 
exact mechanism of action and the chemical entity responsible of the selective anti-metastatic 
activity is not yet fully understood. The first part of this study was designed to define a 
structure-activity relationship, among 5 metal-based compounds, with the aim to identify the 
features conferring to a molecule the ability to interfere with the metastatic progression. For 
this purpose the heterocyclic ruthenium compounds KP1019 and KP418, were selected and 
compared to the organometallic compounds RM175, AFAP51 and RAPTA-T. The main 
features that characterize these compounds are the presence of two axial molecules of 
indazole and imidazole, respectively in the structure of KP1019 and KP418; the 
ethylendiamine ligand in RM175 and in its osmium cogener AFAP51, and the PTA ligand in 
the coordination sphere of RAPTA-T. The metastatic progression is mimicked in vitro by 
tests representing the cell detachment, the cell migration, the ECM degradation, the cell 
invasion and the cell re-adhesion to a new growth substrate. Moreover, the comparison of the 
behaviour of the highly invasive breast cancer cell line MDA-MB-231, to that of the non 
tumorigenic HBL-100, allows to highlight any selective action on the metastatic process by 
the examined compounds. The predictive value of the proposed series of tests will be 
ascertained by the in vivo determination of the anti-metastatic activity of the metal-complexes 
in the murine MCa mammary carcinoma model. The expected goal of the first part of the 
work is to identify the chemical characteristics conferring to a ruthenium compound the 
ability to interfere in the metastatic process. In the second part of the work the activity of this 
molecule will be investigated at molecular levels to get some insights on its mechanism of 
action. In the metastatic process it is well known the important role of the cell-ECM 
interactions, involved in the cell adhesion and detachment processes that drive cell motility. In 
all the aforementioned processes integrins are the cell adhesion molecules mainly involved. 
On these basis the molecular investigation will study the modulation of the integrin activity 
by the identified compound. The analysis at cellular level will evaluate the effects of the metal 
compound on the formation of focal contacts and on the reorganization of the actin 
cytoskeleton, both driven by the integrin receptor engagement. At molecular level the study 
will deal with the direct binding of the test compound with integrin molecules and its 
modulation of the integrin interactions with their natural ligands. Moreover, some 
downstream molecules of the integrin signalling pathway will be analyzed, such as the 
RhoGTPases, mainly RhoA straight involved in phenomena like actin reorganization.
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3 MATERIALS AND METHODS 
3.1 Compounds tested 
 
All the compounds tested were prepared accordingly to published procedures: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Chemical structure of KP418 (left) and KP1019 (right). 
 
KP418, HIm[Ru(III)Cl4(Im)2] (Keppler et al, 1987), and KP1019, 
HInd[Ru(III)Cl4(Ind)2] (Lipponer et al, 1996), were synthesized in the Institute of Inorganic 
Chemistry, University of Vienna and kindly supplied by Prof. B.K. Keppler.  
 
 
 
Figure 3.2. Chemical structure of RAPTA-T. 
 
RAPTA-T, Ru(II)Cl2(η6-C7H8) (1,3,5-triaza-7-phosphadamantane) (Scolaro et al, 2005), 
was synthesized in the laboratory of Prof. P.J. Dyson at the Institut des Sciences et Ingénierie 
Chimiques, Laboratoire de Chemie Organométallique, EPFL, Lausanne.  
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Figure 3.3. Chemical structure of RM175 (left) and AFAP51 (right). 
 
RM175, [(η6-biphenyl)Ru(II)Cl(ethylendiamine)]PF6 (Morris et al, 2001), and AFAP51 
[(η6-biphenyl) Os(II)Cl(ethylendiamine)]BF4 (Peacock et al, 2006) were synthesized in the 
School of Chemistry, University of Edinburgh in the laboratory of Prof. P.J. Sadler. 
Stock solutions were freshly prepared by dissolving KP418 and RAPTA-T in water, and 
KP1019, RM175 and AFAP51 in DMSO to obtain a concentration of 10-2 M. 
3.2 Cell lines for in vitro tests 
MDA-MB-231 (kindly supplied by Dr P. Spessotto, Cro, Aviano, Italy) 
The MDA-MB-231 human highly invasive cell line is derived from a breast 
adenocarcinoma. This cell line is derived from the pleural effusion of a 51 years old caucasian 
woman. These cells grow in vitro forming a monolayer and have an epithelial-like 
morphology. They do not present estrogen’s receptors, this is a reason of their malignancy. 
They are maintained in Dulbecco’s modified Eagle’s medium (Euroclone®, Devon, UK) 
supplemented with 10% fetal bovine serum (FBS, Gibco, Invitrogen™, Paisley, Scotland, 
UK), 2 mM L-glutamine (Euroclone®, Devon, UK), 1% nonessential amino acids (Sigma-
Aldrich® Chemical Co., St. Louis, Mo, USA) and 100 IU/mL penicillin and 100 µg/mL 
streptomycin (Euroclone®, Devon, UK). 
 
HBL-100 (kindly supplied by Dr G. Decorti, Department of Life Sciences, University of 
Trieste, Italy) 
It is a human non tumorigenic epithelial cell line isolated from a 27 years old mother’s 
milk. The HBL-100 cell line grows in vitro forming a monolayer adherent cell culture. They 
are maintained in McCoy’s 5A medium (Sigma-Aldrich® Chemical Co., St. Louis, Mo, USA) 
supplemented with 10% FBS, 2 mM L-glutamine, and 100 IU/mL penicillin and 100 µg/mL 
streptomycin. 
Ru
Cl NH2NH2
PF6-
+
Os
Cl NH2NH2
BF4-
+
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Growth conditions and cell culture maintenance 
All cell lines were kept in a CO2 incubator with 5% CO2 and 100% relative humidity at 
37°C. Cells from a confluent monolayer were removed from flasks to create sub-cultures. The 
procedure is here reported: 
 medium is discarded and cells are washed once with Calcium Magnesium Free Dulbecco’s 
Phosphate Buffered Saline (CMF-DPBS), to remove cell debris and medium residues; 
 cells are removed from the flask using a trypsin-EDTA solution (Sigma-Aldrich® 
Chemical Co., St. Louis, Mo, USA), for 2 minutes at 37°C; to prevent trypsin damaging of 
the cells they are collected in a tube with culture medium in the same volume as trypsin; 
 the cell suspension is centrifuged for 7 minutes at 4°C 300 xg to get a pellet of cells; 
 cell viability is determined by the Trypan Blue exclusion test; 
 cells are seeded in flasks or multiwell cell culture plates with the appropriate medium. 
Trypan Blue exclusion test 
This test allows the determination of the viability of the cells. Trypan Blue (figure 3.4) 
is a positively charged dye unable to enter vital cells. Dead cells have a damaged membrane 
and Trypan Blue can enter these cells conferring them a blue colour whereas live cells appear 
a clear yellow. After dilution with the Trypan Blue solution, cells are counted by using a 
Bürker chamber (Cook and Mitchell, 1989). 
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Figure 3.4. Trypan Blue chemical structure 
Solutions used 
Calcium Magnesium Free Dulbecco’s Phosphate Buffered Saline (CMF-DPBS) 
 NaCl (Sigma-Aldrich® Chemical Co., St. Louis, Mo, USA), 137 mM; 
 KCl (AnalaR∗, The British Drug Houses Chemicals, Ltd, Poole, England), 2.7 mM; 
 Na2HPO4 (Antibioticos S.p.A., Carlo Erba Reagenti, Rodano, Milano, Italy), 8 mM; 
 KH2PO4 (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 1.5 mM; 
 H2O distilled. 
The pH of the solution is about 7.4. CMF-DPBS is filtrated by using filter paper, then 
sterilized in autoclave at 121°C for 15 minutes and 1 atmosphere. 
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Trypsin/EDTA 
It is a solution used for removing adherent cells, it contains tetrasodic EDTA 2 g/L and 
trypsin 5 g/L (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), it is diluited 10 times in 
sterile CMF-DPBS at the moment of use. 
Trypan Blue solution 
It contains 0.2% w/v Trypan Blue (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) 
and 3 mM sodium azide (AnalaR∗, The British Drug Houses Chemicals, Ltd, Poole, England) 
in CMF-DPBS. The Trypan Blue solution is filtered and kept at 4°C. The solution used for 
tests is further diluted 1:2 in non sterile CMF-DPBS and conserved at 4°C. 
3.3 Preparation of cell culture substrates 
Cell culture plates were coated with different substrates belonging to the extra cellular 
matrix (ECM): fibronectin (from human plasma, Sigma-Aldrich Chemical Co., St. Louis, 
MO, USA), collagen IV (from human placenta, Sigma-Aldrich Chemical Co., St. Louis, 
MO, USA) and Matrigel®, a basal membrane extract (from mouse tumour, BD, Biosciences, 
San Josè, CA); for comparison purposes on poly-L-lysine (Sigma-Aldrich Chemical Co., St. 
Louis, MO, USA), a substrate on which cells simply adhere by electrostatic interactions, was 
also used. 
Proper concentrations of substrates, i.e. 20 µg/mL of fibronectin, 20 µg/mL (or 0.2 
µg/mL or 0.3 µg/mL for the experiment described in paragraph 3.5.2, or 5 µg/mL for the 
experiment described in paragraph 3.15) of collagen IV, 20 µg/mL Matrigel® and 10 µg/mL 
of poly-L-lysine were prepared in sterile water, added on cell culture plates and left in a 
humified cell-culture chamber at 37°C for 4 hours. Then plates were washed with CMF-
DPBS and non specific adhesion sites were blocked with 0.1% w/v BSA in CMF-DPBS for 
30 minutes. Then plates were washed again and at this point they were ready for cell seeding. 
3.4 Resistance to detachment assays 
This assay measures the cells ability to resist the trypsin mediated detachment. It was 
used to evaluate:  
1) The resistance to detachment induced by different metal-based compounds 
2) The resistance to detachment induced by RAPTA-T in cells pre-treated with a Rho 
inhibitor 
3) The resistance to detachment induced by RAPTA-T in cells immediately after adherence  
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1) Resistance to detachment induced by different metal-based compounds 
In 96 well plastic plates (Corning Costar, Milano, Italy), previously coated as described 
above (paragraph 3.3) with poly-L-lysine, fibronectin and 20 µg/mL collagen IV, 6·103 cells 
in 0.2 mL of complete medium were seeded in each well. After 2 days at 37°C, complete 
medium was replaced with serum-starved medium containing 0.1% w/v BSA. After 24 hours 
the medium was removed and the plates washed with CMF-DPBS. Cells were treated for 1 
hour at 37°C with KP418, KP1019, RAPTA-T, RM175 and AFAP51 dissolved in DPBS 
(Dulbecco’s Phosphate Buffered Saline) at the concentration of 10-4 M. 
At the end of the treatment the solutions containing the compounds were removed, the 
plates were washed twice with CMF-DPBS, and a 0.008% w/v trypsin solution was added to 
each well. Plates were kept in agitation for 30 minutes at room temperature, then trypsin 
solution was removed and wells washed with CMF-DPBS. The cells that still adhere to the 
plate were detected by the sulforhodamine B (SRB) test. Resistance to detachment is 
expressed as arbitrary units, calculated by dividing the mean absorbance of treated cells by the 
mean absorbance of control cells. 
2) Resistance to detachment induced by RAPTA-T in cells pre-treated with a Rho inhibitor 
96 well plastic plates were coated as described in paragraph 3.3 with poly-L-lysine, 
fibronectin, 20 µg/mL collagen IV, 6·103 cells in 0.2 mL of complete medium were seeded in 
each well. After 2 days at 37°C, complete medium was replaced with serum-starved medium 
containing 0.1% w/v BSA. After 24 hours half of the wells in each plate were incubated for 4 
hours with a solution of 3 µg/mL of highly purified C3 transferase, linked to a proprietary cell 
penetrating moiety (Cell Permeable Rho Inhibitor -Cytoskeleton, Denver, CO) that selectively 
inactivate the GTPases RhoA, RhoB, RhoC. At the end of the treatment with the Rho 
inhibitor, the cells were treated for 1 hour with RAPTA-T at the concentrations of 10-6,10-5 
and 10-4 M. 
At the end of the treatment the cells were processed as described at point 1). 
3) The resistance to detachment induced by RAPTA-T in cells immediately after adherence 
Different conditions were used to evaluate the effect of RAPTA-T on detachment 
immediately after cell adhesion. The cells, grown for 24 hours in serum-starved medium, 
containing 0.1% w/v BSA, were removed from flasks by a trypsin-EDTA solution, collected 
by centrifugation, re-suspended in serum starved medium supplemented with 0.1% w/v BSA 
and kept for 30 minutes at room temperature to allow surface receptor reconstitution. 4·104 
cells in 0.2 mL of complete medium were then seeded in each well of 96 well plastic plates 
previously coated as described in the paragraph 3.3 with poly-L-lysine, fibronectin and 20 
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µg/mL collagen IV. The cells were left to adhere for 1 hour at 37°C, with 5% CO2 and 100% 
relative humidity, then non adherent cells were washed off and adherent cells were treated 
with RAPTA-T at the concentrations of 10-6,10-5 and 10-4 M for 1 hour at 37°C. 
At the end of the treatment, the cells were processed as described at point 1). 
3.5 Adhesion assay 
Cell ability to adhere was studied in different situations: 
1) Adhesion assay treating cells in adhesion with different metal-based compounds 
2) Adhesion assay treating cells in suspension with RAPTA-T 
3)Adhesion assay after pre-treatment of the substrates with RAPTA-T 
 
1) Adhesion assay treating cells in adhesion with different metal-based compounds 
Cells maintained for 24 hours in serum-starved medium were then treated for 1 hour 
with KP418, KP1019, RAPTA-T, RM175 and AFAP51 dissolved in DPBS at the 
concentration of 10-4 M. At the end of the treatment, the cells were removed from flasks with 
a trypsin-EDTA solution, collected by centrifugation, re-suspended in serum starved medium 
supplemented with 0.1% w/v BSA and kept for 30 minutes at room temperature to allow 
surface receptor reconstitution. 104cells in 0.1 mL of complete medium were seeded in each 
well of a 96 well plastic plates, previously coated as described in paragraph 3.3 with poly-L-
lysine, fibronectin, 20 µg/mL collagen IV and Matrigel®. The cells were left to adhere for 1 
hour at 37°C with 5% CO2 and 100% relative humidity, then the medium containing the non 
adherent cells was removed and the wells were gently washed with CMF-DPBS. The cells 
that in 1 hour had adhered to the substrates were detected by the SRB test. 
2) Adhesion assay treating cells in suspension with RAPTA-T 
The ability of the cells to adhere during RAPTA-T treatment was evaluated in cells 
maintained for 24 hours in serum-starved medium, and then removed from flasks as described 
above at point 1). Then the cells were seeded on 96 well plastic plates, previously coated as 
described in the paragraph 3.3 with collagen IV (at the concentration of 0.3 µg/mL for MDA-
MB-231 cells line or 0.2 µg/mL for HBL-100 cells), at a density of 4·104 cells in 0.1 mL/well 
of a solution of RAPTA-T at the concentrations of 10-6, 10-5 and 10-4 M in DPBS. The cells 
were left to adhere 1 hour at 37°C, then the treatment containing the non adherent cells was 
removed and wells were gently washed with CMF-DPBS. The cells adherent to the substrates 
were detected by the crystal violet assay test. 
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3)Adhesion assay after pre-treatment of the substrates with RAPTA-T 
The aim of this series of experiments was to evaluate if RAPTA-T bound to the 
substrates could affect cell adhesion. 96 well plastic plates were coated as described in the 
paragraph 3.3 with poly-L-lysine, fibronectin and 20 µg/mL collagen IV. Then substrates 
were treated with RAPTA-T dissolved in DPBS at the concentrations of 10-6,10-5 and 10-4 M 
for 1 hour. At the end of the treatment wells were washed 3 times with CMF-DPBS, then 
cells, maintained for 24 hours in serum-starved medium and removed from flasks as described 
above at point 1), were seeded at a density of 4·104 cells in 0.1 mL/well. The cells were left to 
adhere for 1 hour at 37°C with 5% CO2 and 100% relative humidity, then the medium 
containing the non adherent cells was removed and wells were gently washed with CMF-
DPBS. The cells that after 1 hour were adherent to the substrates were detected by the SRB 
test. 
3.6 Sulforhodamine B (SRB) assay 
The adherent cells were detected with the SRB test (Skehan et al,1990). Adherent cells 
were fixed with 10% v/v trichloroacetic acid (TCA) at 4°C for 1 hour. After fixation TCA 
was discarded and the wells washed five times with distilled water and air-dried. 0.4% w/v 
SRB solution was added to the wells and plates were kept for 30 minutes at room 
temperature. Unbound SRB was removed by washing three times with 1% v/v acetic acid. 
The plates were air dried, then bound stain was dissolved with un-buffered 10mM Tris base 
(tris-hydroxymethyl-aminomethane) and the optical density was read at 570 nm with an 
automatic computerised spectrophotometer (SpectraCount™; Packard, Meriden, CT). 
Solutions used 
Dulbecco’s Phosphate Buffered Saline (DPBS) 
 NaCl, 137 mM; 
 KCl, 2.7 mM; 
 Na2HPO4, 8 mM; 
 KH2PO4, 1.5 mM; 
 CaCl2 · 2H2O (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 0.88 mM; 
 MgCl2 · 6H2O (AnalaR∗, The British Drug Houses, Chemicals, Ltd, Poole, England) 0.5 
mM; 
 H2O distilled. 
The first four reagents are dissolved in water. The last two components are dissolved 
separately in a small amount of water. CaCl2  and MgCl2 solutions are added drop by drop 
under stirring  to avoid salt precipitation. Deionised H2O is used to fill the volume. The final 
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solution is sterilized by using a 0.20 µm filter (Corning Incorporated, Costar Italia, Milano, 
Italy). 
BSA 
BSA solution contains 50 mg/mL BSA (Sigma-Aldrich Chemical Co., St. Louis, MO, 
USA) dissolved in CMF-DPBS and is sterilized by using a 0.20 µm filter. 
Trypsin  
Trypsin solution contains 0.008% w/v trypsin (Sigma-Aldrich Chemical Co., St. 
Louis, MO, USA) dissolved in CMF-DPBS. 
Trichloroacetic acid 
Trichloroacetic acid (TCA) solution contains 10% v/v of TCA (Sigma-Aldrich 
Chemical Co., St. Louis, MO, USA) diluted in distilled H2O. 
Sulforhodamine B 
Sulforhodamine B (SRB) solution contains 0.4% w/v of SRB (Sigma-Aldrich 
Chemical Co., St. Louis, MO, USA) dissolved in a solution of 1% v/v acetic acid (Sigma-
Aldrich Chemical Co., St. Louis, MO, USA). 
Tris base 
This solution is prepared dissolving 10 mM Tris base (Sigma-Aldrich Chemical Co., 
St. Louis, MO, USA), pH equal to 10.5, in distilled H2O. 
3.7 Migration assays 
Migratory ability resulting from a haptotactic or a chemotactic stimulus was measured 
using Transwell® cell culture chambers (Costar, Milano, Italy). 
 
 
Figure 3.5. Schematic of a Transwell® insert showing the separation of apical and basolateral chambers by a 
permeable membrane with a confluent cell monolayer on the apical surface, (Saunders, 2009). 
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Haptotaxis assay 
In the haptotaxis assay the lower surface of the polyvinylpyrrolidone-free polycarbonate 
filter (8 µm pore size) was coated with 10 µg/mL fibronectin, as stimulus for the migration of 
the cells, or with 0.1% w/v BSA (negative control), left in a humified cell culture chamber at 
37°C for 2 hours, and washed with CMF-DPBS before cell seeding. 
The cells were treated for 1 hour with KP418, KP1019, RAPTA-T, RM175 and 
AFAP51 dissolved in DPBS at the concentration of 10-4 M and KP1019 is used also at the 
following concentrations: 10-6 M for MDA-MB-231 and 10-5 M for HBL-100. After treatment 
the cells were removed with a trypsin-EDTA solution, collected by centrifugation, re-
suspended in serum starved medium supplemented with 0.1% w/v BSA and 1·105 cells in 0.2 
mL of serum starved medium supplemented with 0.1% BSA, were seeded in the upper 
compartment of each chamber. The lower compartment was filled with serum starved medium 
supplemented with 0.1% w/v BSA. 
Chemotaxis assay 
In the chemotaxis assay inserts were used without coating, because the stimulus for the 
migration of the cells is given by the presence of 10% v/v FBS in the medium in the lower 
compartment of the Transwell®. The cells were treated and seeded as previously described in 
the haptotaxis assay. The lower compartment was filled with serum starved medium 
supplemented with 0.1% w/v BSA (negative control), or with complete medium (positive 
control).  
 
In haptotaxis and chemotaxis assays the cells were left to migrate for 24 hours, then the 
cells on the upper surface of the filters were removed with a cotton swab and the migrating 
cells, present in the lower surface, were detected by the crystal violet assay. 
3.8 Invasion assay 
This assay is used to measure the ability of the cells to invade the extracellular matrix in 
a Transwell® cell culture chamber according to the method of Albini et al (Albini et al., 
1987). The upper surface of the polyvinylpyrrolidone-free polycarbonate filter (8 µm pore 
size) was coated with a 600 µg/mL Matrigel® solution and air dried overnight at room 
temperature. The filters were reconstituted with DMEM medium for 90 minutes under gentle 
shaking immediately before use. Cells were treated as described for the migration assays and 
0.5·105 cells in 0.2 mL of serum starved medium supplemented with 0.1% BSA, were seeded 
in the upper compartment of each chamber. The lower compartment was filled with complete 
medium supplemented or not (negative controls) with 10% FBS as pro-invasive factor. The 
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cells were left to invade for 96 hours in the incubator, then the cells on the upper surface of 
the filters were removed with a cotton swab and invading cells, present in the lower surface, 
were detected by the crystal violet assay. 
Matrigel® 
 Matrigel, 600 µg/mL; 
 DMEM low. 
3.9 Crystal violet assay 
The crystal violet assay was performed according to the method described by Kueng et 
al (Kueng et al, 1989). The cells migrated to the under surface of the filters of the Transwell® 
chambers were fixed with 0.7 mL of a 1.1% v/v glutaraldehyde (Sigma-Aldrich Chemical 
Co., St. Louis, MO, USA) solution for 15 minutes under gentle shaking. After fixation the 
cells were washed with deionized water three times and air dried. The cells were first stained 
for 20 minutes with 0.1% w/v crystal violet prepared in 200 mM borate buffer, then washed 
three times with deionized water and air dried prior to dissolve the dye with 10% v/v acetic 
acid solution. The optical density was read at 590 nm with an automatic computerised 
spectrophotometer (SpectraCount™; Packard, Meriden, CT). 
In the case of adhesion assay, described in the paragraph 3.5.2, the cells adherent to the 
plate were fixed for 7 minutes with 70% v/v ethanol, washed twice with CMF-DPBS and 
stained for 30 minutes with 0.1% w/v crystal violet in 200 mM borate buffer; unbound stain 
was removed by washing two times with water. Before the dissolution of crystal violet, 
images of the cells were acquired with Olimpus K71 software MetaVue™ imaging system, 
with magnification 220X. Then crystal violet was dissolved with ethanol 90% and the optical 
density was measured by a multiwell plate reader (BioTek, Bad Friedchshall, Germany). 
Solution used 
Borate buffer 
 Boric acid (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 200 mM; 
 Ethanol (Antibioticos S.p.A., Carlo Erba Reagenti, Rodano, Milano, Italy), 2% v/v; 
 H2O deionized. 
The pH of the solution is equal to 9. 
3.10 Zymography 
Zymoanalysis is used for the detection of the gelatinolytic activity of MMP-2 and 
MMP-9 enzymes. 
The cells at 70% confluence were incubated for 24 h in serum-starved medium 
containing 0.1% w/v BSA, before being treated for 1 hour with KP418, KP1019, RAPTA-T, 
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RM175 and AFAP51 dissolved in DPBS at the concentration of 10-4 M. At the end of the 
treatment the compound solution was discarded and complete serum-free medium containing 
0.1% w/v BSA was added for a further 24 h, when culture media were collected, centrifuged 
to remove cellular debris, then concentrated approximately 15 times using Amicon ® Ultra -15 
30,000 nominal molecular weight limit centrifugal filter devices (Millipore Corporation, 
Bedford, MA). The conditioned media obtained were stored at -80°C until use.  
Protein content measurement by the Bradford method  
Total protein content was measured by the Bradford method (Bradford, 1976), based on 
the bond of proteins with Bradford solution. Bradford solution contains Coomassie Brilliant 
Blue G-250 stain dissolved in orto-phosphoric acid and methanol (Sigma-Aldrich Chemical 
Co., St. Louis, MO, USA). The assay is based on the observation that the absorbance 
maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 
nm when binding to protein occurs. Both hydrophobic and ionic interactions stabilize the 
anionic form of the dye, causing a visible colour change. The absorbance at 595 nm is directly 
proportional on protein concentration. 
A standard curve was made using serial diluitions from 1 mg/mL to 0.005 mg/mL of 
BSA dissolved in deionized water.  
96 multiwell non-treated plates were used for the protein content measurement. Protein 
samples were appropriately diluted in distilled water, then 200µL/well of Bradford reagent 
were added both to samples and to standard and absorbance was read by spectrophotometer at 
590 nm wavelength (SpectraCount™; Packard, Meriden, CT). 
Electrophoretic run 
Electrophoresis on polyacrylamide gel permits to separate proteins on the basis of their 
chemico-physical characteristics. Proteins denaturated thanks to the presence of SDS in the 
gel are therefore separated according to their molecular weight. 
The electrophoresis chamber is assembled as described: 
 running gel is prepared and the chamber is filled with it; 
 a small volume of water-saturated isobutanol (Antibioticos S.p.A., Carlo Erba Reagenti, 
Rodano, Milano, Italy) is poured on the top. Isobutanol hydrates the gel and avoids bubbles 
formation. When the gel is polymerized, isobutanol is removed and gel is washed with 
water; 
 stacking gel is prepared and poured into the chamber. A small comb is fixed into the gel to 
form small wells. When the gel is polymerized, the comb is taken off and the wells are 
washed three times with distilled water; 
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 the electrophoresis chamber is built (Mini PROTEAN 3, Bio-Rad Laboratories, Hercules, 
CA, USA) and electrode buffer added; 
 equal amounts of proteins for each sample are diluted with non-reducing Laemmli sample 
buffer and deionized water. Samples and molecular weights (6.5 kDa -205 kDa Sigma-
Aldrich Chemical Co., St. Louis, MO, USA) are loaded; 
 the samples are subjected to electrophoresis, under denaturalizing but non-reducing 
conditions, at a costant voltage of 70mV and 13 mA for 150-180 minutes. 
After electrophoresis, gel is gently detached and washed in 2.5% v/v TritonX-100 
solution, (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) twice for 30 minutes at 4°C, 
to remove SDS. After additional washings in water (three times for five minutes each to 
remove Triton X-100) the gel is incubated at 37°C overnight, in collagenase buffer to re-
activate gelatinase activity: proteases are able to exert proteolytic activity on the co-
polymerized substrate. Subsequently the gel is stained with 0.5% w/v Coomassie Brilliant 
Blue (Bio-Rad Laboratories, Hercules, CA, USA), in constant rotation, to underline 
proteolysis areas appearing as clear bands against a blue background. Intensive destaining 
solution is used to make bands clearer. Quantitative evaluation of band intensity, on the basis 
of gray levels, is performed using Image Master 2D version 4.01 Magic Scan 32 version 4.3 
software. 
Solutions used 
Electrophoresis gel 
Running gel  
 Acrylamide/bisacrylamide 29:1 (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 
10% w/v; 
 Tris base pH 8.8, 375 mM;  
 SDS: sodium dodecyl sulfate (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 0.2% 
w/v; 
 Gelatin (Bio-Rad Laboratories, Hercules, CA, USA), 0.06 % w/v; 
 Ammonium persulfate (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 0.1% w/v; 
 TEMED (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 0.01% v/v; 
 Deionized H2O. 
Stacking gel  
 Acrylamide/bisacrylamide 29:1, 3.75% w/v; 
 Tris base pH 6.8, 375 mM; 
 SDS, 0.2% w/v; 
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 Ammonium persulfate, 0.1% w/v; 
 TEMED, 0.01% v/v; 
 Deionized H2O. 
LaemmLi sample buffer 4X (non reducing) 
 Tris HCl (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) pH 6.8, 0.125M;  
 SDS, 8% w/v; 
 Glicerol (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 10% w/v; 
 Bromofenol Blue (Bio-Rad Laboratories, Hercules, CA, USA), 0.005% w/v; 
 Deionized H2O. 
Electrode buffer 
 Tris base, 50 mM; 
 Glycin (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 384 mM; 
 SDS, 0.1% w/v; 
 Deionized H2O. 
TritonX-100 
 TritonX-100 (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 2.5% v/v; 
 Deionized H2O. 
Collagenases buffer  
 Tris HCl, 50 mM;  
 NaCl, 200 mM; 
 CaCl2 · 2 H2O, 5 mM;  
 Deionized H2O. 
Coomassie Blue 
 Coomassie Blue R-250 (Bio-Rad Laboratories, Hercules, CA, USA), 0.5% w/v; 
 Methanol (CH3OH) (Antibioticos S.p.A., Carlo Erba Reagenti, Rodano, Milano, Italy), 
30% v/v; 
 Acetic acid (CH3COOH) (Antibioticos S.p.A., Carlo Erba Reagenti, Rodano, Milano, 
Italy), 10% v/v; 
 Deionized H2O. 
De-staining solution 
 CH3OH, 30% v/v; 
 CH3COOH, 10% v/v; 
 Deionized H2O. 
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3.11 Cell viability 
To evaluate if the treatment with the compounds, in the experimental conditions 
adopted, can affect cell viability, the cells were treated as described above for migration tests, 
but they were seeded on 96 well plates. After 24 h the cell viability was measured by the MTT 
assay: a solution of MTT was added to each well (10 µL per 100 µL of medium) and the 
plates were incubated at 37°C with 5% CO2 and 100% relative humidity for 4 h. After this 
time, the medium was discarded and 200 µL of DMSO was added to each well to dissolve the 
formazan crystals (Alley at al, 1988). The optical density was measured at 570 nm with an 
automatic computerised spectrophotometer (SpectraCount™; Packard, Meriden, CT). 
Solution used 
MTT 
The MTT solution contains 5 mg/mL MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) 
dissolved in CMF-DPBS and is sterilized by using a 0.20 µm filter. 
3.12 Immunofluorescence 
Effects of RAPTA-T treatment on cell cytoskeleton 
To observe actin filaments and paxillin, MDA-MB-231 and HBL-100 were seeded on 
multiwell slides (LabTek®, Nalge Nunc International, Naperville, USA) previously coated as 
described in paragraph 3.3 with poly-L-lysine, fibronectin and 20 µg/mL collagen IV. Then 
6·104 cells in 0.3 mL of complete medium were seeded in each well. After 2 days at 37°C, 
complete medium was replaced with serum-starved medium, containing 0.1% w/v BSA. After 
24 hours the medium was removed and the wells washed with CMF-DPBS. The cells were 
treated for 1 hour with RAPTA-T dissolved in DPBS at the concentrations of 10-6,10-5 and 10-
4
 M. At the end of the treatment, cells were washed with CMF-DPBS, and fixed for 10 
minutes with 4% w/v paraformaldeyde (Sigma-Aldrich Chemical Co., St. Louis, MO, USA). 
Cell permeabilization was performed by treating cells for 2 minutes with a solution containing 
0.1% v/v Triton X- 100 and 4% v/v FBS. Then the cells were washed with 0.1% w/v 
BSA/CMF-DPBS, and aspecific sites were blocked using 2% v/v goat serum solution for 20 
minutes. Then cells were incubated for 1 hour with the anti-paxillin primary antibody 1:500 
(1MAB 3060, Chemicon International Inc., Temecula CA, USA) in 0.1% w/v BSA/CMF-
DPBS; at the end of the incubation, the primary antibody was removed and the cells were 
washed with 0.1% w/v BSA/CMF-DPBS. At this point the cells were incubated for 1 hour 
with a solution containing the secondary antibody, a goat anti-mouse IgG Alexa Fluor 546 
(Molecular Probes, Eugene, OR, USA), at the concentration of 1:400 and at the same time 
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with Phalloidin, Alexa Fluor 488 conjugated at 4 U/mL (Molecular Probes, Eugene, OR, 
USA) in 0.1% w/v BSA/CMF-DPBS. At the end of the incubation the cells were washed with 
CMF-DPBS and the slides mounted using Mowiol 4-88 (Calbiochem, San Diego, CA, USA). 
Images were acquired with a confocal system MRC-1024 (Bio-Rad Laboratories, 
Hercules, CA, USA), using a Bio-Rad LaserSharp confocal software.  
 
Effects of RAPTA-T treatment on cell cytoskeleton pre-treating cells with Rho inhibitor 
To evaluate the effects of RAPTA-T on cytoskeleton after inhibition of Rho, the cells 
were incubated with a solution of 3 µg/mL of the Rho inhibitor (described in paragraph 3.4) 
for 4 hours before the 1 hour treatment with RAPTA-T dissolved in DPBS at 10-6,10-5 and 10-
4
 M. 
At the end of the treatment the cells were processed as described above. 
3.13 Immunocytochemistry 
The activation of β1 integrin was qualitatively evaluated using immunocytochemistry. 
MDA-MB-231 cells were seeded on multiwell slides (LabTek®, Nalge Nunc International, 
Naperville, USA) previously coated as described in paragraph 3.3 with poly-L-lysine, 
fibronectin and 20 µg/mL collagen IV. Then 6·104 cells in 0.3 mL of complete medium were 
seeded in each well. After 2 days at 37°C, complete medium was replaced with serum-starved 
medium, containing 0.1% w/v BSA. After 24 hours the medium was removed and the wells 
washed with CMF-DPBS. The cells were treated for 1 hour with RAPTA-T dissolved in 
DPBS at the concentrations of 10-6,10-5 and 10-4 M. At the end of the treatment, cells were 
washed with CMF-DPBS, and fixed for 10 minutes with 4% w/v paraformaldeyde (Sigma-
Aldrich Chemical Co., St. Louis, MO, USA). Cell permeabilization was performed by 
treating cells for 2 minutes with a solution containing 0.1% v/v Triton X- 100 and 4% v/v 
FBS, then washed with 0.1% w/v BSA/CMF-DPBS. The inhibition of endogenous 
peroxidises was performed keeping the cells in contact with H2O2 3% in methanol for 20 
minutes. Then the cells were washed with 0.1% w/v BSA/CMF-DPBS, and aspecific sites 
were blocked for 20 minutes with a horse serum solution (1:70). Then the cells were 
incubated for 90 minutes with the primary antibody, mouse anti-human integrin β1 active, 
1:500 in CMF-DPBS (clone n°2Q839, USBiological, Swampscott, Massachusset, USA), 
while negative controls were incubated with mouse serum (1:500); at the end of the 
incubation, the primary antibody was removed and the cells were washed with CMF-DPBS. 
At this point the cells were incubated for 30 minutes with a solution containing the secondary 
antibody, a horse anti-mouse IgG biotinylated (Vector laboratories, Inc, Burlingame, CA, 
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USA) prepared in a horse serum solution (1:70) at the concentration 1:300. Vectastatin® 
Elite® ABC kit (Vector laboratories, Inc, Burlingame, CA, USA), containing avidin and 
horseradish peroxidise biotinylated, was used for the amplification of the signal of biotin,. 
Then the cells were kept in contact with diaminobenzide tetrachloride (DAB) for 30 seconds 
(Sigma Fast , 3,3-Diaminobenzidine tablet sets) (Sigma). Then the cells were counter-stained 
with methyl-green 0.2% w/v in water for 10 seconds. At the end of the incubation the cells 
were washed with CMF-DPBS and the slides mounted using glycerol (SIGMA, St. Louis, 
MO, USA). Images were acquired with light microscope (Orthoplan, Leitz, Germany) with 
magnification 800X.  
Solutions used 
Paraformaldeyde (PAF) 
 PAF, 4% w/v;  
 CMF-DPBS. 
Triton-X solution 
 Triton X-100, 0.1% v/v; 
 FBS, 4% v/v; 
 CMF-DPBS /BSA 0.1% w/v. 
Goat serum solution 
 Goat serum 2%v/v;  
 CMF-DPBS /BSA 0.1% w/v. 
Horse serum solution 
 Horse serum 1:70;  
 CMF-DPBS /BSA 0.1% w/v. 
Methyl-green solution 
 Methil-green 0.2% w/v 
 Deionized H2O 
3.14 RhoA activation assay 
To measure the effect of RAPTA-T on the activation of RhoA, in MDA-MB-231 and in 
HBL-100 cells, a RhoA activation assay kit was used (Kit # BK124, Cytoskeleton, Inc., 
Denver, CO). This assay exploit a Rho-GTP-binding protein linked to the wells of a 96 well 
plate. Active, GTP bound Rho, in cell lysates binds to the wells, while inactive, GDP bound 
Rho, is removed during washing steps. The bound GTP RhoA is detected by incubation with 
a RhoA specific antibody followed by a secondary antibody conjugated to horseradish 
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peroxidase (HRP) and followed by an HRP detection reagent. For the collection of samples 
for the assay, 6 well plates were coated with poly-L-lysine, fibronectin and 20µg/mL collagen 
IV, as described in paragraph 3.3, then 5·104 cells in 2 mL of complete medium were seeded 
in each well. Cells at 50% confluence were incubated for 24 hours in serum-starved medium 
containing 0.1% BSA. At this point the cells were treated for 1 hour with RAPTA-T dissolved 
in DPBS at the concentrations of 10-6,10-5 and 10-4 M. In parallel, as negative control, a 
sample was treated for 4 hours with a solution of 3 µg/mL of Rho inhibitor (described in 
paragraph 3.4) in serum-starved medium and, as positive control, a sample was treated for 1 
hour with the RhoA activator, 2 µg/mL Cytocalasin D (Sigma-Aldrich Chemical Co., St. 
Louis, MO, USA) in serum-starved medium. At the end of the treatments the cells were 
lysated using the lysis buffer with protease inhibitors included in the kit. The lysate protein 
concentration was detected using the precision redTM advanced protein assay reagent 
included. At this point to measure RhoA activation, the G-LISATM activation kit was used 
according to the manufacturer’s instructions. The signal was read by measuring the 
absorbance at 490 nm using a microplate reader (Spectra Count Packard). 
3.15 Determination of ruthenium associated with the cells and the substrates 
The association of ruthenium with the cells and the substrates was determined by atomic 
absorption spectroscopy (AAS) on samples processed using the procedure of Tamura and 
Arai with slight modifications (Tamura and Arai, 1992). 
 
Determination of ruthenium associated with cells 
The plastic plates, 100·20mm, were coated as described above in paragraph 3.3 with 
poly-L-lysine, fibronectin and 20 µg/mL collagen IV. Then 4·105 cells in 9 mL of complete 
medium were seeded in each plate. After 2 days at 37°C, complete medium was replaced with 
serum-starved medium, containing 0.1% w/v BSA. After 24 hours the medium was removed 
and the plates washed with CMF-DPBS. Cells were treated with RAPTA-T at the 
concentrations of 10-6,10-5 and 10-4 M dissolved in DPBS, added to the plates and incubated 
for 1 hour, and for the concentration 10-4 M also for 15 and 30 minutes. After the treatment, 
the cells were washed three times with CMF-DPBS, then collected and counted with Trypan 
Blue exclusion test, and the concentration of ruthenium associated with cells was determined 
as follows. 
The cells were dried in Nalgene cryogenic vials (a first drying step was performed 
overnight at 80°C and a second step at 105°C until the samples reached a constant weight). 
The dried cells were decomposed by the addition of an aliquot of tetramethylammonium 
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hydroxide (25% v/v in water) (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) and of 
milliQ water at a ratio of 1:1 directly in each vial, at room temperature and under shaking. 
Final volumes were adjusted to 1 mL with milliQ water. 
Determination of ruthenium bound with substrates under cells 
The concentration of the ruthenium bound with the substrates on which cells treated 
with RAPTA-T have been seeded, was also evaluated. To collect the substrates after the 
removal of the cells that were on them, the substrates were put in direct contact with 
tetramethylammonium hydroxide (25% v/v in water) and of milliQ water at a ratio of 1:2, and 
then the solution was collected in a vial. The samples at this point were ready for the 
determination of the ruthenium content. 
Determination of ruthenium bound with substrates 
For the determination of the ruthenium associated to the substrates alone, plates were 
coated as described above in paragraph 3.3 with poly-L-lysine, fibronectin and 20 µg/mL 
collagen IV, then they were treated for 1 hour with RAPTA-T dissolved in DPBS at the 
concentrations of 10-6,10-5 and 10-4 M, and for the concentration 10-4 M also for 15 and 30 
minutes. At the end of the treatment, substrates were dissolved with the addition of 
tetramethylammonium hydroxide (25% v/v in water) and of milliQ water at a ratio of 1:2 
directly in each plate. After collecting this solution, the samples were ready for the 
determination of the ruthenium content. 
 
The concentration of ruthenium in the cells and bound with the substrates, was 
measured in triplicate by flameless atomic absorption spectroscopy (AAS) using a Zeeman 
graphite tube atomizer, model SpectrAA-300, supplied with a specific ruthenium emission 
lamp (hollow cathode lamp P/N 56-101447-00; Varian, Mulgrave, Victoria, Australia). 
Quantification of ruthenium was carried out in 10 µL samples at 349.9 nm with an atomizing 
temperature of 2500°C, using argon as carrier gas at a flow rate of 3.0 L/min. Before each 
analysis, a five-point calibration curve was obtained to check the range of linearity using a 
ruthenium custom-grade standard, 988 mg/mL (Inorganic Ventures, Lakewood,NJ). 
3.16 Hydrolysis of RAPTA-T in aqueus and buffered solution with the addition of 
substrates 
As a collaboration within the COST D39 consortium, in the laboratory of Prof. P.J. 
Dyson EPFL (Switzerland), some experiments were performed to analyse the interaction of 
RAPTA-T with substrates used in the previously described experiments (i.e. poly-L-lysine, 
fibronectin and collagen IV). The experiment was carried out solubil
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T in mixture (0.6 mL of substrate solution + 0.1 mL of D2O) or (0.4 mL of substrate solution 
+ 0.2 mL of DPBS + 0.1 mL of D2O). 31P NMR spectra were recorded in 20 minutes after 
mixing. For the experiment in water 31P NMR was recorded also after 5 hours. 1H and 
31P{1H} NMR spectra are recorded by using a Bruker Avance DPX 400 instrument 
(Ultrashield Magnet) at 400.13 (1H), and 161.98 MHz (31P) at 298 K. The purity of RAPTA-T 
is confirmed by 1H, 31P NMR and elemental analysis. The experiment was kindly performed 
by Dr Alexey Nazarow (EPFL, Switzerland). 
3.17 Flow cytometry 
The expression of the α1β1 integrin on the surface of MDA-MB-231 and HBL-100 cells 
was detected using flow cytometry. The cells were maintained for 24 hours in serum-starved 
medium and removed from flasks as described above. Then 2·105 cells in 0.2 mL/well were 
transferred into microtiter-wells and centrifuged at 300xg for 2 minutes. The supernatants 
were taken off and the cells were washed with 0.2 mL of CMF-DPBS. At this point the 
blocking buffer was added for 20 minutes at 37°C. At the end of the block half of the samples 
were incubated for 1 hour at 37 °C with 0.1 mL of 5 µg/mL primary antibody anti α1 (MAB 
1973, Millipore Corporation, Bedford, MA) or  with a rabbit polyclonal antiserum against the 
human β1 integrin. Then the cells were washed and then incubated for 45 minutes at 37 °C 
with 0.1 mL of secondary antibody R-phycoerytrin goat anti-mouse IgG (Gibco, 
Invitrogen™, Paisley, Scotland, UK) 1:500, or with the same concentration of goat anti-rabbit 
IgG Alexa Fluor 647-R-phycoeryhrin (Gibco, Invitrogen™, Paisley, Scotland, UK) 
respectively for detection of α1 or β1 integrin chains. Before performing a flow cytometry 
scan, the cells were filtered through a nylon gauze (140 µm pore size) into flow cytometry 
vials. Samples were read with the flow cytometer CyFlow® (Partec GmbH, Germany). 
Solution used  
Blocking buffer 
 Horse serum 1 % w/v in CMF-DPBS. 
3.18 Detection of ruthenium bind with integrins 
As a collaboration within the COST D39 consortium, some experiments were 
performed to analyse the interaction between integrin and RAPTA-T. In the laboratory of the 
Center for Molecular Medicine in the University of Frankfurt Prof. J.A Eble and co-workers 
have produced and isolated integrin α1β1 (as described in Eble and Berditchevski, 2001), the 
integrin was separated by gel-filtration on TSK2000XLGW column after treatment with 10 
mM EDTA to remove any divalent cations from the protein. Fractions were eluted with 10 
mM sodium phosphate buffer, pH 7.5, 150 mM NaCl and monitored for protein contents by 
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absorbance at 254 nm. Fractions with α1β1 integrin were identified with SDS-PAGE, which 
proves the correct molecular weights of the integrin subunits. The integrin solution 
(containing Mg2+, ions in TRIS -buffered salin, pH > 7.4) was sent to the laboratory of the 
Prof. P.J. Dyson were 10-4 M RAPTA-T were added to the integrin-solution (ratio RAPTA-T 
: integrin ca 20:1) and incubated over night (16 hours) at 37°C. Then, the sample was applied 
to a sephadex200 gel filtration column and eluted in 100 mM ammonium acetate buffer, pH 
equal to 7.4, the eluate of the gel filtration column was immediately injected to the ICP-MS 
detection in order to quantify the Ru2+-ion concentration. These experiments was kindly 
performed by Dr Michael Groessl in the laboratory of Prof. P.J. Dyson (EPFL, Switzerland). 
3.19 Titration of soluble α1β1 integrin with RAPTA-T 
As a collaboration within the COST D39 consortium in the laboratory of Prof. J.A Eble, 
in the Center for Molecular Medicine (University of Frankfurt). The study of the interference 
of RAPTA-T treatment, in the bind of the α1β1 integrin with its ligand collagen IV was 
performed. 
The titration of soluble α1β1 integrin (produced as described by Eble and Berditchevski, 
2001) with/without RAPTA-T was performed with slight modifications of the procedures 
previously described (Eble and Berditchevski, 2001). 96 well plates were coated with 5 
µg/mL of collagen IV in Tris Buffered Saline /Mg2+ (TBS/Mg) at 4°C overnight. After a 
double washing, the wells were blocked with 0.1% w/v BSA in TBS/Mg2+ and then soluble 
α1β1 integrin at different concentrations was incubated with the collagen IV with or without 
the presence of RAPTA-T 10-4 M dissolved in TBS/Mg2+, or with 1mM MnCl2 (positive 
control) or 10mM EDTA (negative control) for 2 hours at room temperature. Then the 
unbound integrin was washed off with HEPES buffer whereas bound integrin was fixed to the 
wells with 2.5% v/v glutaraldehyde solution in HEPES buffer for 10 minutes and quantified 
with ELISA using a rabbit polyclonal antiserum against the human β1 integrin and a 
secondary anti rabbit IgG-antibody (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), 
conjugated to alkaline phosphatase (both diluted 1:1000 in BSA/TBS/Mg). Conversion of p-
nitro-phenyl-phosphate (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), was measured 
by a multiwell plate reader (BioTek, Bad Friedrichshall, Germany) at 405nm. After 
subtracting negative control. Values were generally determined in duplicate. 
Solution used 
Tris Buffered Saline /Mg2+ (TBS/Mg2+) 
 Tris/HCl, 50mM (Sigma-Aldrich® Chemical Co., St. Louis, MO, USA); 
 NaCl, 150 mM; 
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 MgCl2, 2 mM. 
The pH of the solution is 7.4. 
HEPES buffer 
 HEPES, 50 mM (Sigma-Aldrich Chemical Co., St. Louis, MO, USA); 
 NaCl, 150 mM; 
 MgCl2, 2 mM; 
 MnCl, 1 mM. 
The pH of the solution is 7.4. 
3.20 In vivo Tests 
The in vivo experiments were carried out with the murine mammary carcinoma (MCa), 
originally obtained from the department of Biology, Rudjer Boskovich Institute (Zagreb, 
Croazia), grown in CBA female mice, obtained from a local breeding colony grown according 
to the standard procedures for inbred strains. The tumor line was locally maintained by serial 
biweekly passages of 106 viable tumour cells, of a cell suspension prepared from mincing 
(with scissors) the primary tumour masses obtained from donors similarly implanted 2 weeks 
before. The minced tissue was filtered through a double layer of sterile gauze, centrifuged at 
250 x g for 10 minutes, and re-suspended in an equal volume of CMF-DPBS; the viable cells 
were counted by Trypan Blue exclusion test. 106 viable tumour cells were injected 
i.m.(intramuscular) into the left hind calf of experimental groups.  
KP1019 was administrated as 10% v/v DMSO solution in sterile saline (0.9% NaCl) 
and given to mice by i.p. (intra peritoneal) injections at two dose levels of 40 mg/kg/day from 
day 6 to day 11 after tumour implant, and 80 mg/kg/day on days 7, 9 and 11 after tumour 
implant (the doses of the treatments used were based on data reported in Keppler et al, 1989). 
RAPTA-T was dissolved in physiological saline and given to mice by i.p. (intra peritoneal) 
administrations of 80 mg/kg/day on days 8, 9 and 12 after tumour implant (the doses of the 
treatments used were based on data reported in Scolaro et al, 2005). RM175 and AFAP51 
were administrated as 10% v/v DMSO solution in sterile saline (0.9% NaCl) and given to 
mice by i.p. (intra peritoneal) injections at two dose levels of 7.5 mg/kg/day and 10 
mg/kg/day for six consecutive days, starting when primary tumour became palpaple, i.e. from 
day 8 to 13 after tumour implant for both RM175 and AFAP51 at dose 7.5 mg/kg/day (the 
doses of the treatments used were based on data reported in Aird et al, 2002 for RM175, and 
used for the cogener AFAP51 also). The effects of 10 mg/kg/day of RM175 were evaluated in 
a separate experiment starting the treatment on day 6 after tumour implant; as RM175 at this 
dose level was toxic the treatment was stopped after four consecutive injections. 
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Primary tumour growth was determined by calliper measurements, by measuring two 
orthogonal axes, and the tumour volume was calculated with the formula: (Л/6)xa2xb, where a 
is the shorter axis and b the longer axis, assuming tumour density equal to 1 g/mL. The 
evaluation of the number and weight of lung metastases was performed by examining the 
surface of the lungs immediately after sacrificing the animals by cervical dislocation. The 
lungs were dissected into five lobes, washed with CMF-DPBS and examined under a low 
power microscope equipped with a calibrated grid. The weight of each metastasis was 
calculated by applying the same formula used for primary tumours and the sum of each 
individual weight gave the total weight of metastatic tumour per animal. 
3.21 Animal Studies 
Animal studies were carried out according to guidelines enforced in Italy (DDL116 of 
21/2/1992 and subsequent addenda) and in compliance with the Guide for the Care and Use of 
Laboratory Animals (Deparment of Health and Human Services Publ. No. 86-23, Bethesda, 
MD, NIH, 1985). 
3.22 Statistical analysis 
The results were subjected to computer-assisted statistical analysis using the One-Way 
Analysis of Variance ANOVA, and the Tukey-Kramer post-test. Differences of P<0.05 were 
considered to be significantly different from the controls. 
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4 RESULTS 
SCREENING OF RUTHENIUM-BASED COMPOUNDS IN AN IN VITRO 
SIMULATION OF THE METASTATIC DISSEMINATION 
This first part of the study focuses on a screening aimed to investigate in vitro how 
differences in the chemical structure of ruthenium compounds can affect the formation of 
secondary tumours. For this purpose two heterocyclic compounds HIm[Ru(III)Cl4(Im)2] 
(KP418) and HInd[Ru(III)Cl4(Ind)2] (KP1019), and three organometallic compounds, [(η6-
biphenyl)Ru(II)Cl(ethylendiamine)]PF6 (RM175), its osmium congener [(η6-
biphenyl)Os(II)Cl(ethylendiamine)]BF4 (AFAP51), and Ru(II)Cl2(η6-C7H8)(PTA) (RAPTA-
T, PTA = 1,3,5-triaza-7-phosphoadamantane) were chosen. The potential anti-metastatic 
activity of these compounds was evaluated as the interference with some steps of the 
metastatic progression, mimed in vitro by appropriate functional tests. These tests were done 
by comparing the behaviour of the highly invasive breast cancer cell line MDA-MB-231 to 
that of the non tumorigenic mammary cell line HBL-100. To evaluate how the proposed in 
vitro model can predict the in vivo metastasis inhibition, validation experiments with the MCa 
mammary carcinoma were performed in the CBA mouse. 
4.1 Effects of metal-based compounds on resistance to detachment 
The first step of the metastatic process is represented by the detachment of invasive 
tumour cells from the primary tumour. This effect is simulated in vitro by examining the 
effects of the metal compounds on the propensity of cells to detach after seeding on 
components of the extracellular matrix (ECM) such as fibronectin (F) and collagen IV (C) 
and, for comparison, on poly-L-lysine (P) a substrate where cells adhere by electrostatic 
interactions rather than by adhesion molecules, and exposing the treated cells to a diluted 
trypsin solution. 
As shown in figure 4.1, after trypsin exposure untreated HBL-100 cells are able to 
remain adherent more strongly than untreated MDA-MB-231 cells, to all the substrates taken 
into consideration. The differences between the two cell lines on the same substrate are 
significant from a statistic point of view. Moreover the capability of HBL-100 cells to remain 
adherent to the substrate, after the contact with the enzyme, is more evident on cells grown on 
fibronectin or on poly-L-lysine than on collagen IV. All the differences are relevant also from 
a statistic point of view. 
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Figure 4.1. Behaviour of control cells in the resistance to detachment assay. MDA-MB-231 and HBL-100 cells 
seeded 72 hours before on 96-well plastic plates previously coated with poly-L-lysine, fibronectin and collagen 
IV, are exposed for 1 hour to DPBS and then to a diluted trypsin solution for 30 minutes, before detecting cells 
still attached to the growth substrate by the SRB assay. ANOVA and Tukey Kramer post test: bars labelled with 
the same letter are statistically different: a, P<0.001; b, P<0.001; c, P<0.05; d, P<0.05; e, P<0.01; f, P<0.001. 
 
Considering the effects of the treatments with the compounds reported in figure 4.2, it is 
evident that KP418 shows an effect only on the MDA-MB-231 cells grown on fibronectin (4-
times increase, statistically significant versus controls). On the highly invasive cells seeded on 
poly-L-lysine there is a two fold increase of adherent cells, while on collagen IV, and when 
HBL-100 cells are used, the treatment has a negligible effect. KP1019 shows a similar 
qualitative effect: the greatest activity is detected on MDA-MB-231 cells grown on 
fibronectin (5 fold increase of adherent cells). KP1019 has significant effects also on MDA-
MB-231 cells grown on poly-L-lysine and collagen IV, more pronounced than that of KP418. 
Taking into consideration the non tumorigenic cell line, the effects of KP1019 treatment are 
weaker, even though their being  statistically significant.  
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Figure 4.2. Effects of KP418 and KP1019 on resistance to detachment. MDA-MB-231 and HBL-100 cells 
seeded 72 hours before on 96-well plastic plates previously coated with poly-L-lysine, fibronectin and collagen 
IV, are exposed for 1 hour to the compounds 10-4 M and then to a diluted trypsin solution for 30 minutes, before 
detecting cells still attached to the growth substrate by the SRB assay. Arbitrary units are calculated from the 
mean ± S.D. of two experiments, each performed in quadruplicate and controls are set equal to 1, and 
represented as a line on the graph. ANOVA and Tukey Kramer post test: bar labelled with the same letter are 
statistically different: a, P<0.05; b, P<0.05; c, P<0.05; d, P<0.01;and *, P<0.05; **, P<0.01; ***, P<0.001 versus 
relevant controls. 
 
Considering the organometallic compounds, RAPTA-T is able to statistically increase 
the number of MDA-MB-231 cells that remain adherent to the ECM substrates after challenge 
with trypsin. Data of figure 4.3 show that, after trypsin exposure, there is a 6-fold increase of 
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cells that remain adherent on fibronectin, and an 8-times greater cell density, in comparison to 
controls, when MDA-MB-231 are grown on collagen IV. By contrast on poly-L-lysine there 
is only a 2-fold increase of cells resistant to trypsin. When the non tumorigenic HBL-100 cells 
are used the effects of RAPTA-T on poly-L-lysine are the same observed in the highly 
invasive cell line, while on the ECM components the effects are totally negative.  
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Figure 4.3. Effects of RAPTA-T on resistance to detachment. MDA-MB-231 and HBL-100 cells seeded 72 
hours before on 96-well plastic plates previously coated with poly-L-lysine, fibronectin and collagen IV, are 
exposed for 1 hour to the compounds 10-4 M and then to a diluted trypsin solution for 30 minutes, before 
detecting cells still attached to the growth substrate by the SRB assay. Arbitrary units are calculated from the 
mean ± S.D. of two experiments, each performed in quadruplicate and controls are set equal to 1, and 
represented as a line on the graph. ANOVA and Tukey Kramer post test: *, P<0.05; ***, P<0.001 versus 
relevant controls. 
 
RM175 also affects selectively the resistence to trypsin harvesting by acting on MDA-
MB-231 cells only, but without any specificity for ECM substrates; moreover its effect is 3-4 
times lower than that of RAPTA-T. On the contrary the osmium derivative AFAP51, an 
analogue of RM175, from which it differs for the metal centre only, induces modifications of 
cell capability to resist to detachment on the non tumorigenic HBL-100 cells only, increasing 
their ability to adhere on poly-L-lysine and decreasing this ability when cells are grown on 
ECM components. The effects on HBL-100 are all statistically significant. 
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Figure 4.4. Effects of RM175 and AFAP51 on resistance to detachment. MDA-MB-231 and HBL-100 cells 
seeded 72 hours before on 96-well plastic plates previously coated with poly-L-lysine, fibronectin and collagen 
IV, are exposed for 1 hour to the compounds 10-4 M and then to a diluted trypsin solution for 30 minutes, before 
detecting cells still attached to the growth substrate by the SRB assay. Arbitrary units are calculated from the 
mean ± S.D. of two experiments, each performed in quadruplicate and controls are set equal to 1, and 
represented as a line on the graph. ANOVA and Tukey Kramer post test: *, P<0.05; **, P<0.01; ***, P<0.001 
versus relevant controls. 
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4.2 Effects on migration and invasion 
These tests mimic the process which, after the detachment from the primary tumor, 
enable a cell to migrate, extending cellular protrusions, and to invade the surrounding tissues. 
This study was done using properly adapted Transwell® chambers. In the migration assays 
(figure 4.5), the cells were subjected to a chemical (chemotaxis) or to a contact (haptotaxis) 
stimulus to promote cell movement; in the invasion assay (figure 4.6) chambers were coated 
with a 3D matrix.  
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Figure 4.5. Effects of KP418, KP1019, RAPTA-T, RM175 and AFAP51 on migration of cells through 
polycarbonate filters. MDA-MB-231 and HBL-100 cells were sown 72 hours before the treatment, for 1 hour, 
with the compounds at the concentration of 10-4 M and KP1019# is equal to 10-6M for MDA-MB-231 and 10-
5M for HBL-100, then the cells were removed from the flasks, collected, resuspended and seeded on the inserts 
of cell-culture chambers. Data represent cells that after 24 hours are migrated and are present on the lower 
surface of the filter. Data are the percent of variation versus controls calculated from the mean ± S.D. of two 
experiments, each performed in triplicate. ANOVA and Tukey Kramer post test: *, P<0.05; **, P<0.01; ***, 
P<0.001 versus relevant controls. 
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The treatment with 10-4 M KP418 is devoid of effects in both migration tests while 10-4 
M KP1019, among all the tested compounds, causes the most pronounced reduction, - 70% of 
migrated cells versus controls, in both cell lines, this effect is not found when KP1019 is used 
at lower concentrations. RAPTA-T reduces (-50%) in a statistically significant manner the 
migration of the highly invasive cell line MDA-MB-231 only, while being ineffective on the 
non tumorigenic HBL-100 cell line. Treatment with 10-4 M RM175 predominantly leads to a 
statistically significant inhibition of haptotaxis in both cell lines, while the osmium compound 
AFAP51 inhibits chemotaxis only. 
The invasive ability of the cells is not affected by KP418, RM175 and AFAP51 
treatment, while, also in this situation, 10-4 M KP1019 treatment leads to a pronounced (-80% 
versus controls), and statistically significant inhibition of invasion of both cell lines, also in 
this case lower concentrations of KP1019 are devoid of effects. RAPTA-T treatment reduces 
in a statistically significant manner only the invasion of the highly invasive cell line MDA-
MB-231, whereas it has no effect on the non tumorigenic HBL-100 cells. 
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Figure 4.6. Effects of KP418, KP1019, RAPTA-T, RM175 and AFAP51 on invasion of cells through Matrigel®. 
MDA-MB-231 and HBL-100 cells were sown 72 hours before the treatment, for 1 hour, with the compounds at 
the concentration of 10-4 M and KP1019# is equal to 10-6 M for MDA-MB-231 and 10-5 M for HBL-100, then 
the cells were removed from the flasks, collected, resuspended and seeded on the inserts of cell-culture 
chambers. Data represent cells that after 96 hours are invaded and are present on the lower surface of the filter. 
Data are the percent of variation versus controls calculated from the mean ± S.D. of two experiments, each 
performed in triplicate. ANOVA and Tukey Kramer post test: **, P<0.01; ***, P<0.001 versus relevant controls. 
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4.3 Effects on MMPs activity 
A cancer cell to invade a 3D matrix has to produce and activate enzymes able to 
degrade it. In particular, in this work we took into consideration the two main important 
gelatinases (MMP-2 and MMP-9), and the effects of the test compounds on the matrix 
metalloproteinases activity were studied with conventional gelatine zymography test. MDA-
MB-231 cells produce the 92KDa MMP-9 in appreciable amounts, whereas HBL-100 cells 
prevalently produce the 72 KDa MMP-2. KP1019 reduces the gelatinolitic activity of both 
gelatinases by approximately 70% (figure 4.7, histogram) as regards to the untreated controls, 
KP418 reduces MMP-9 activity only by about 40%. 
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Figure 4.7. Effects of KP418 and KP1019 treatment on MMPs activity. MDA-MB-231 and HBL-100 cells were 
sown 72 hours before the treatment for 1 hour with the compounds at the concentration of 10-4 M, then 
incubated for additional 24 hours in serum-starved complete medium containing 0.1% BSA. Supernatants 
containing MMPs were collected and concentrated and equal protein amounts (100 µg) subjected to SDS-PAGE. 
Gelatine digestion by proteases is detected as white bands against the blue background. Band digestion is 
quantified by using Image Master 2D version 4.01 and Magic Scan 32 version 4.3 software. 
 
 
RAPTA-T treatment reduces the gelatinolitic activity of MMP-9 produced by MDA-
MB-231 by 30% (figure 4.8, histogram) versus untreated controls, whereas it has no effect on 
the activity of gelatinases harvested from HBL-100 cells. 
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Figure 4.8. Effects of RAPTA-T treatment on MMPs activity. MDA-MB-231 and HBL-100 cells were sown 72 
hours before the treatment for 1 hour with the compounds at the concentration of 10-4 M, then incubated for 
additional 24 hours in serum-starved complete medium containing 0.1% BSA. Supernatants containing MMPs 
were collected and concentrated and equal protein amounts (100 µg) subjected to SDS-PAGE. Gelatine digestion 
by proteases is detected as white bands against the blue background. Band digestion is quantified by using Image 
Master 2D version 4.01 and Magic Scan 32 version 4.3 software. 
 
AFAP51 reduces the MMP-9 activity by 25% versus controls, while RM175 is inactive. 
Both compounds are able to inhibit the activity of MMP-2 by 65% versus controls (figure 4.9, 
histogram), independently of the cell line source. 
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Figure 4.9. Effects of RM175 and AFAP51 treatment on MMPs activity. MDA-MB-231 and HBL-100 cells 
were sown 72 hours before the treatment for 1 hour with the compounds at the concentration of 10-4 M, then 
incubated for additional 24 hours in serum-starved complete medium containing 0.1% BSA. Supernatants 
containing MMPs were collected and concentrated and equal protein amounts (100 µg) subjected to SDS-PAGE. 
Gelatine digestion by proteases is detected as white bands against the blue background. Band digestion is 
quantified by using Image Master 2D version 4.01 and Magic Scan 32 version 4.3 software. 
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4.4 Effects on cell viability 
To exclude the involvement of direct cell cytotoxicity in the strong effects showed by 
some compounds in the previous tests, an MTT assay was performed using the same 
experimental conditions adopted in the functional assays: cells were treated for 1 hour at the 
concentration of 10-4 M and after 24 hours cell viability was measured (figure 4.10). 
KP418 causes a 20% reduction, statistically significant versus controls, of the growth of 
the highly invasive cell line MDA-MB-231, whereas it has no effects on the non tumorigenic 
HBL-100 cells. KP1019 is cytotoxic for both cell lines, significantly reducing cell viability by 
40% and 70%, respectively in MDA-MB-231 and HBL-100 cells. Looking at the effects of 
organometallic compounds, they do not induce significant oscillations of cell viability in 
comparison to the relevant controls. 
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Figure 4.10. Effects of KP418, KP1019, RAPTA-T, RM175 and AFAP51 on cell viability. MDA-MB-231 and 
HBL-100 cells were grown for 72 hours before the treatment for 1 hour with the compounds at the concentration 
10-4 M, then the cells were removed from the flasks, collected, resuspended and seeded on 96 well plates. After 
24 hours cell viability was determined by the MTT assay. Data represent the percentage of alive cells in each 
treated group versus the relevant controls (T/C%), calculated from the mean ± S.D. of two experiments, each 
performed in quadruplicate, controls are equal to 100, and represented as a line on the graph. ANOVA and 
Tukey Kramer post test: *, P<0.05; ***, P<0.001 versus controls.  
 
 
4.5 Effects on re-adhesion after treatment of cells in adhesion 
The last step of the metastatic progression taken into consideration is the capability of 
cells to grow in a distinct site, that here was mimicked by the ability to re-adhere on 
fibronectin (F), collagen IV (C), poly-L-lysine (P) and Matrigel® (M). The study was done by 
exposing the highly invasive cell line (MDA-MB-231) and the non tumorigenic one (HBL-
100) to 1 hour treatment with KP418, KP1019, RAPTA-T, RM175 and AFAP51 at the 
concentration of 10-4 M, then scraping off the cells and seeding them on a new substrate. 
Figure 4.11 shows the ability of control cells to re-adhere to the different substrates. 
Untreated HBL-100 cells seem able to adhere more quickly than the untreated MDA-MB-231 
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cells. In particular after 1 hour the amount of the non tumorigenic cells adhering on the 
extracellular component fibronectin, is higher than that of the highly invasive cells (difference 
statistically significant). Moreover HBL-100 cells seems to adhere better on poly-L-lysine and 
on fibronectin, than on collagen IV and on Matrigel®. By contrast, MDA-MB-231 cells 
adhere much slowly on ECM proteins (fibronectin, collagen IV) and Matrigel® than on poly-
L-lysine. 
KP418 and KP1019 do not significantly alter the capability of these cells to re-adhere to 
the test substrates (figure 4.12).  
The organometallic compound, RAPTA-T (figure 4.13) causes a reduction of 80% of 
the ability to re-adhere of the highly invasive cell line, independently of the ECM component 
tested (fibronectin or collagen IV) or of Matrigel® itself, with similar effects also on poly-L-
lysine. By contrast RAPTA-T does not affect the capability to re-adhere of cells of the non 
tumorigenic cell line.  
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Figure 4.11. Behaviour of control cells in the re-adhesion assay. MDA-MB-231 and HBL-100 cells were grown 
for 72 hours before the treatment for 1 hour with DPBS, then the cells were removed from the flasks, collected, 
resuspended and seeded on 96 well plastic plates previously coated with poly-L-lysine, fibronectin, collagen IV 
and Matrigel ®. After 1 hour of incubation cells that adhered to the substrates were detected by the SRB assay. 
Data are the mean ± S.D. of the optical density at 570nm of two experiments, each performed in triplicate. 
ANOVA and Tukey Kramer post test: *, P<0.05; MDA-MB-231 versus HBL-100, comparison among 
substrates.  
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Figure 4.12. Effects on the ability of cells to re-adhere after KP418 and KP1019 treatment. MDA-MB-231 and 
HBL-100 cells were grown for 72 hours before the treatment with the compounds for 1 hour at the concentration 
of 10-4 M, then the cells were removed from the flasks, collected, resuspended and seeded on 96 well plastic 
plates previously coated with poly-L-lysine, fibronectin, collagen IV and Matrigel ®. After 1 hour cells that 
adhered to the substrates were detected by the SRB assay. Data are the percent of variation versus controls 
calculated from the mean ± S.D. of two experiments, each performed in triplicate. 
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Figure 4.13. Effect on the ability of cells to re-adhere after RAPTA-T treatment. MDA-MB-231 and HBL-100 
cells were grown for 72 hours before the treatment with the compounds for 1 hour at the concentration of 10-4 
M, then the cells were removed from the flasks, collected, resuspended and seeded on 96 well plastic plates 
previously coated with poly-L-lysine, fibronectin, collagen IV and Matrigel ®. After 1 hour cells that adhered to 
the substrates were detected by the SRB assay. Data are the percent of variation versus controls calculated from 
the mean ± S.D. of two experiments, each performed in triplicate. ANOVA and Tukey Kramer post test.: **, 
P<0.01; ***, P<0.001 versus relevant controls. 
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RM175 and AFAP51 induce only slight modifications of the cell ability to re-adhere 
(figure 4.14). In particular, the exposure to RM175 significantly reduces the adherence to 
poly-L-lysine and collagen IV of HBL-100 cells only. 
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Figure 4.14. Effect on the ability of cells to re-adhere after KP418, KP1019, RAPTA-T, RM175 and AFA51 
treatment. MDA-MB-231 and HBL-100 cells were grown for 72 hours before the treatment with the compounds 
for 1 hour at the concentration of 10-4 M, then the cells were removed from the flasks, collected, resuspended 
and seeded on 96 well plastic plates previously coated with poly-L-lysine, fibronectin, collagen IV and Matrigel 
®
. After 1 hour cells that adhered to the substrates were detected by the SRB assay. Data are the percent of 
variation versus controls calculated from the mean ± S.D. of two experiments, each performed in triplicate. 
ANOVA and Tukey Kramer post test: *, P<0.05 versus relevant controls. 
 
4.6 Effects on primary tumour and on lung metastases in vivo  
The effects on primary tumour growth and on lung metastases formation of the 
compounds KP1019, RAPTA-T, RM175 and AFAP51, were studied in the model of MCa 
mammary carcinoma, a murine transplantable tumour that spontaneously metastasises to the 
lungs. The doses of the treatments with the metal-based compounds, were chosen in relation 
to what reported in literature: for KP1019 were used reported data from Keppler (1989); for 
RAPTA-T were used data reported from Scolaro et al (2005); in the case of RM175 were used 
data reported from Aird et al (2002) and the same were used for the cogener AFAP51. 
KP1019 given at 40 mg/kg/day from day 6 to day 11 after tumour implant, or 80 
mg/kg/day on days 7, 9 and 11, causes a comparable effect on lung metastasis, as shown in 
figure 4.15, lower panel, and in tables 4.1 and 4.3. In particular, it is completely ineffective in 
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reducing metastasis number, and the effect on metastasis weight is not significant because of 
the great variability among the experimental groups. Considering the effects on primary 
tumour, a statistically significant reduction is evident after the treatment with the higher dose 
only, and it is more pronounced at the end of the treatment schedule than a week later (figure 
4.15, upper panel). 
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Figure 4.15 Effects on primary tumour (upper panel) and on lung metastases (lower panel) of KP1019, RAPTA-
T, RM175 and AFAP51 at different treatment schedules. Groups of CBA mice were inoculated i.m. with 106 
MCa tumour cells on day 0. KP1019 was given at 40 mg/kg/day on days 6 ÷ 11 after tumour implant, and at 80 
mg/kg/day on days 7, 9 and 11; RAPTA-T was given at 80 mg/kg/day on days 8, 9 and 12 after tumour implant; 
RM175 was given at 7.5 mg/kg/day on days 8 ÷ 13 after tumour implant, and at 10 mg/kg/day on days 6 ÷ 9; 
AFAP 51 was given at 7.5 mg/kg/day on days 8 ÷ 13 after tumour implant, and at 10 mg/kg/day on days 8 ÷ 13. 
Data are expressed as the percentage (T/C% ±S.D) of the treated versus relevant controls, and represented on 
graph with a line. Lung metastases were determined on day 20 after tumour implant. Animals free of 
macroscopically detectable metastases are excluded from the calculation of the mean. ANOVA and Tukey 
Kramer post test: ***: P < 0.001 versus controls. 
 64 
Table 4.1 Effects on primary tumour and on lung metastases of KP1019 and RM175. 
 
Primary tumour weight (mg) Lung metastases a 
 
Day 13 Day 20 Number Weight (mg) Mice free 
Controls 1627 ± 286 3068 ± 616 29.2 ± 8.1 18.6 ± 12.1 3/8 
KP1019 40 mg 1095 ± 592 2537 ± 563 31.9 ± 19.2 11.8 ± 11.8 0/8 
RM175 10 mg 768±292 2353±420 4.5±3.3 0.861±0.749 0/4 
Different groups of 10 CBA mice were inoculated i.m. with 10 6 MCa tumour cells on day 0: a control group 
was treated i.p. with sterile saline (0.9% NaCl); a group was treated i.p. with KP1019 at 40 mg/kg/day from day 
6 to day 11 after tumour implant; a group was treated i.p. with RM175 10 mg/kg/day from day 6 to day 9 after 
tumour implant. a lung metastases were determined on day 20 after tumour implant. 
 
RAPTA-T, given at 80 mg/kg/day on days 8, 9 and 12 after tumour implant, only 
marginally affects primary tumour growth on day 13 (i.e. 24 h after the last compound 
injection, figure 4.15 upper panel and table 4.2), and this effect is lost after the end of 
administration. Despite the negligible reduction of the primary tumour, RAPTA-T is able to 
selectively counteract the development and growth of lung metastases, in particular reducing 
metastasis weight to 35% of controls (figure 4.15 lower panel). The inhibition of metastasis 
weight is caused by the decrease of the number of metastases of large dimensions (diameter 
≥2 mm) in the treated group, where only 2 out of 8 mice show them in comparison to 7 out of 
9 mice in the control group. 
 
Table 4.2 Effects on primary tumour and on lung metastases of RAPTA-T and RM175. 
 
Primary tumour weight (mg) Lung metastases a 
 
Day 13 Day 20 Number Weight (mg) Mice free 
Controls 884±202 2455±376 24.4±15.8 8.99±6.50 0/9 
RAPTA-T 80mg 682±170 2443±389 19.4±11.9 3.19±4.10 0/8 
RM175 7.5 mg 466±125 2042±321 8.7±7 3±5.2 4/10 
Different groups of 10 CBA mice were inoculated i.m. with 10 6 MCa tumour cells on day 0: a control group 
was treated i.p. with sterile saline (0.9% NaCl); a group was treated i.p. with RAPTA-T at 80 mg/kg/day on days 
8, 9 and 12 after tumour implant; a group was treated i.p. with RM175 7.5 mg/kg/day from day 8 to day 13 after 
tumour implant. a lung metastases were determined on day 20 after tumour implant. Animals free of 
macroscopically detectable metastases are excluded from the calculation of the mean. 
 
RM175 (7.5 mg/kg/day from day 8 to 13 after tumour implantation and 10 mg/kg/day 
from day 6 to 9), reduces the growth of the primary tumour, measured on day 13, to 
approximately 50% of untreated controls. After treatment withdrawal, the primary tumour 
starts to grow again and, on day 20 an inhibition of 20% and 30% was detected respectively 
for the two doses (figure 4.15 upper panel, tables 4.1 and 4.2). RM175 affected also the 
development and growth of lung metastases (figure 4.15 lower panel, tables 4.1 and 4.2). 
Metastases reduction was evident with both the doses and consists in a reduction by about 
70% of the mean number and weight with the treatment at the dose of 7.5 mg/kg/day; 4 out of 
10 animals were free of macroscopically detectable metastases. A more pronounced reduction 
of 85% and 95%, respectively for metastases number and weight, was recorded in the case of 
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the higher daily dose of 10 mg/kg/day. Nevertheless, at this daily dose a strong toxicity is 
registered with 6 out of 10 treated animals having died before the evaluation of lung 
metastases. In the same experimental model AFAP51, administered at the same dose levels 
used for RM175, is practically inactive, with a negligible inhibition of the primary tumour 
growth (-20% versus controls) and no detectable effects on secondary lung tumours (figure 
4.15, table 4.3). 
 
Table 4.3 Effects on primary tumour and on lung metastases of KP1019 and AFAP51. 
 
Primary tumour weight (mg) Lung metastases a 
 
Day 13 Day 20 Number Weight (mg) Mice free 
Controls 1004±174 2415±439 17.5±10 5.7±6.9 0/11 
KP1019 80 mg 527 ± 136 *** 1764 ± 370*** 19.89 ± 23.18 3.43 ± 5.83 2/11 
AFAP51 7.5 mg 837±145 2066±300 19.6±13.3 5.1±5.2 0/9 
AFAP51 10 mg 943±164 2078±407 19.7±14.2 7.4±8.2 0/11 
Different groups of 11 CBA mice were inoculated i.m. with 10 6 MCa tumour cells on day 0: a control group 
was treated i.p. with sterile saline (0.9% NaCl); a group was treated i.p. with KP1019 at 80 mg/kg/day on days 7, 
9 and 11 after tumour implant; a group was treated i.p. with AFAP51 7.5 mg/kg/day or 10 mg/kg/day from day 8 
to day 13 after tumour implant. a lung metastases were determined on day 20 after tumour implant. Animals free 
of macroscopically detectable metastases are excluded from the calculation of the mean. ***: P < 0.001 versus 
controls, ANOVA and Tukey Kramer post test. 
 
The effects of KP418 on primary tumour growth and lung metastases were already 
evaluated  in the Lewis lung carcinoma model (Zorzet et al 2000); the treatment was given i.p. 
at 35 mg/kg/day on days 8 to 13. KP418 treatment, on day 21 after tumour implant, gives a 
statistically significant reduction (P < 0.05) of 40% of primary tumour growth; metastasis 
number and weight were inhibited from 10 to 30% respectively. 
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ROLE OF CELL-ECM INTERACTION IN THE EFFECTS OF RAPTA-T 
From the results previously described, RAPTA-T, among the metal-compounds taken 
into consideration, is the only chemical that shows selectivity towards the highly metastatic 
cell line in vitro and on lung metastases in vivo. 
A preliminary analysis of MDA-MB-231 and HBL-100 cells treated with RAPTA-T, 
and examined at the light microscopy (figure 4.16), showed for the highly invasive cell line a 
modification of cell morphology in comparison to the untreated controls: treated cells were 
more elongated and presented cellular protrusions never evident in the non tumorigenic cells. 
We therefore though it worthwhile to study in more detail the effects of RAPTA-T on cell 
cytoskeleton remodelling.  
                               MDA-MB-231                                                                     HBL-100 
             Controls                         RAPTA-T 10-4 M                 Controls                        RAPTA-T 10-4 M 
Figure 4.16 Effects of RAPTA-T 10-4 M treatment on cell morphology. MDA-MB-231 and HBL-100 cells 
seeded 72 hours before , were treated with RAPTA-T 10-4 M for 1 hour. At the end of the treatment cells were 
fixed with methanol. Images were acquired with light microscopy Orthoplan, Leitz,, magnification 320X. 
4.7 Effects of RAPTA-T on cytoskeleton remodelling 
The functional experiments of cell migration and invasion, previously described in 
paragraph 4.2, showed that RAPTA-T treatment is able to interfere with these cellular 
features, inhibiting them selectively in the highly invasive cell line. Cell motility is a complex 
phenomenon, directly related to an alternate formation and destruction of focal contacts, and 
to the rearrangement of the actin filaments. To analyse if there are cytoskeleton modification 
due to RAPTA-T treatment, an immunofluorescence technique together with confocal 
analysis was used to detect particularly actin filaments and paxillin in MDA-MB-231 and in 
HBL-100 cells, seeded on different substrates. 
On MDA-MB-231 cells grown on poly-L-lysine, 10-6-10-4 M RAPTA-T induces an 
increase in the formation of stress fibres and in the extension of cellular protrusions, indicated 
with the arrows in figure 4.17, which is more pronounced at the lower concentration tested 
(figure 4.17). On poly-L-lysine the formation of focal contacts seems to be not affected by the 
treatment. The effect of the treatment is different when the same cells are grown on 
fibronectin (figure 4.18): in this case there is an evident increase of stress fibres and also of 
focal contacts starting from the treatment with the concentration 10-5 M (see arrows in figure 
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4.18), moreover RAPTA-T at 10-4 M induces the extension of cellular protrusions and the 
acquisition of a spread morphology by cells. On fibronectin the treatment with the lowest 
concentration (i.e. 10-6 M) seems to decrease stress fibres formation and at the same time 
increase the dimensions of focal contacts. When MDA-MB-231 cells are seeded on collagen 
IV, control cells present a more spread morphology (figure 4.19, indicated with arrows) 
compared with the same cells seeded on the other substrates. On collagen IV RAPTA-T 10-4 
M seems to be the only concentration able to increase the formation of stress fibres and focal 
contacts. 
The treatment of the highly invasive cell line grown on both ECM proteins, with the 
highest concentration of the compound, i.e. 10-4 M, seems to promote also actin condensation 
under the cellular membrane; at the same time in this condition there are no focal contacts 
under this cortical actin ring (see arrows in figure 4.18 and 4.19). 
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CONTROLS 
 
RAPTA-T 10-6 M 
 
RAPTA-T 10-5 M 
 
RAPTA-T 10-4 M 
 
ACTIN    PAXILLIN   MERGE 
 
Figure 4.17. Effects of RAPTA-T treatment on cytoskeleton. MDA-MB-231 cells seeded 72 hours before on 
poly-L-lysine, were treated with RAPTA-T 10-6, 10-5 and 10-4 M for 1 hour. At the end of the treatment cells 
were incubated with phalloidin Alexa-Fluor® 488 and with an antibody anti-paxillin. Images were acquired with 
a confocal system MRC-1024 using a Bio-Rad LaserSharp confocal software. Magnification 63X. 
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Figure 4.18. Effects of RAPTA-T treatment on cytoskeleton. MDA-MB-231 cells seeded 72 hours before on 
fibronectin, were treated with RAPTA-T 10-6, 10-5 and 10-4 M for 1 hour. At the end of the treatment cells were 
incubated with phalloidin Alexa-Fluor® 488 and with an antibody anti-paxillin. Images were acquired with a 
confocal system MRC-1024 using a Bio-Rad LaserSharp confocal software. Magnification 63X. 
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MDA-MB-231 collagen IV 
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Figure 4.19. Effects of RAPTA-T treatment on cytoskeleton. MDA-MB-231 cells seeded 72 hours before on 
collagen IV, were treated with RAPTA-T 10-6, 10-5 and 10-4 M for 1 hour. At the end of the treatment cells were 
incubated with phalloidin Alexa-Fluor® 488 and with an antibody anti-paxillin. Images were acquired with a 
confocal system MRC-1024 using a Bio-Rad LaserSharp confocal software. Magnification 63X. 
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When the non tumorigenic cell line HBL-100 are grown on poly-L-lysine (figure 4.20), 
the treatment with RAPTA-T at the concentration of 10-6 M causes a decrease in stress fibres 
formation and an increase of the presence of focal contacts. Increasing the concentration to 
10-5 M, there is the increase of the formation of focal contacts, and also of stress fibres and of 
cortical actin. Treatment with the highest concentration has the main effect of changing the 
morphology of the cells, with an increased number of cellular protrusions; 10-4 M RAPTA-T 
reduces the presence of actin stress fibres in comparison with 10-5M (see arrows in figure 
4.20). On cells seeded on fibronectin (figure 4.21) RAPTA-T does not promote actin 
condensation. Considering stress fibres and focal contact formation, the most evident effect is 
given by the treatment at 10-6 M, and consists of an increase of stress fibres, while the 
presence of focal contacts completely disappears in this treatment condition. When HBL-100 
cells are grown on collagen IV (figure 4.22), 10-6 M RAPTA-T reduced the formation of actin 
stress fibres and of focal contacts (an effect similar to that observed on poly-L-lysine), and 
weakly increased the formation of stress fibres and of focal contacts at 10-5 M. After the 
treatment with the concentration 10-4 M cells present a more spread morphology. 
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Figure 4.20. Effects of RAPTA-T treatment on cytoskeleton. HBL-100 cells seeded 72 hours before on poly-L-
lysine, were treated with RAPTA-T 10-6, 10-5 and 10-4 M for 1 hour. At the end of the treatment cells were 
incubated with phalloidin Alexa-Fluor® 488 and with an antibody anti-paxillin. Images were acquired with a 
confocal system MRC-1024 using a Bio-Rad LaserSharp confocal software. Magnification 63X. 
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Figure 4.21. Effects of RAPTA-T treatment on cytoskeleton. HBL-100 cells seeded 72 hours before on 
fibronectin, were treated with RAPTA-T 10-6, 10-5 and 10-4 M for 1 hour. At the end of the treatment cells were 
incubated with phalloidin Alexa-Fluor® 488 and with an antibody anti-paxillin. Images were acquired with a 
confocal system MRC-1024 using a Bio-Rad LaserSharp confocal software. Magnification 63X. 
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Figure 4.22. Effects of RAPTA-T treatment on cytoskeleton. HBL-100 cells seeded 72 hours before on collagen 
IV, were treated with RAPTA-T 10-6, 10-5 and 10-4 M for 1 hour. At the end of the treatment cells were 
incubated with phalloidin Alexa-Fluor® 488 and with an antibody anti-paxillin. Images were acquired with a 
confocal system MRC-1024 using a Bio-Rad LaserSharp confocal software. Magnification 63X. 
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4.8 RAPTA-T effects on resistance to detachment after inhibition of RhoGTPases 
Among the key molecules involved in the cell migration process, the family of 
RhoGTPases has a central role in the cytoskeleton organization. In particular, stress fibres and 
focal contact formation are directly related with RhoGTPases. With the following 
experiments a possible relation between RhoGTPases and RAPTA-T action was investigated. 
The test described below evaluated which are the effects of RAPTA-T, in MDA-MB-231 and 
HBL-100 cells, after the inhibition of RhoA, RhoB and RhoC, in the resistance to detachment 
assay, a functional test previously described in paragraph 3.4.2. As Rho inhibitor a highly 
purified C3 transferase, linked to a proprietary cell penetrating moiety, was used: this 
inhibitor has the capability to selectively inactivate only the GTPases RhoA, RhoB, RhoC 
(Aktories et al, 2004). 
On the highly invasive cell line, the pre-treatment with the inhibitor induces a 
significant decrease, approximately of 70% (figure 4.23 upper panel), of cell capability to 
resist to trypsin harvesting, when they are grown both on fibronectin and collagen IV. On 
MDA-MB-231 cells grown of fibronectin, the treatment with 10-6 M RAPTA-T does not 
counteract the action of the Rho inhibitor. RAPTA-T treatment at the concentration of 10-5 M 
and in particular of 10-4 M is able to contrast the effect of the inhibitor partially (10-5 M) and 
totally (10-4 M); in fact, the highest dose causes a statistically significant 10 times increase of 
cell resistance to detachment in the cells pre-treated or not with the inhibitor. Similarly, on 
MDA-MB-231 cells grown on collagen IV, RAPTA-T counteract the effect of the inhibitor 
already at the concentration of 10-5 M, and the treatment with the highest concentration totally 
contrasts the effects of the inhibitor, and significantly increases cell capability to resist to 
trypsin harvesting by 6 and two times, respectively in comparison with controls pre-treated or 
not with the inhibitor. All these effects are selectively detected on MDA-MB-231 cells grown 
on ECM proteins; in fact, when cells are seeded on poly-L-lysine there are no detectable 
effects due to the inhibitor or, as already known, due to the RAPTA-T treatment. 
As shown in the lower graph of fig 4.23, the pre-treatment with the Rho inhibitor is not 
able to affect the HBL-100 cells ability to remain adherent to poly-L-lysine and to fibronectin, 
in particular a weak decrease is detectable, only on cells adherent on poly-L-lysine, probably 
biologically irrelevant; on the contrary, on fibronectin, there are no detectable effects. In 
contrast, on HBL-100 cells grown on collagen IV, the Rho inhibitor reduces cells adherent to 
the substrate, after trypsin harvesting, by 70%. RAPTA-T at the lowest concentration used is 
devoid of activity on cells pre-treated with the Rho inhibitor. Treatment at 10-5 M RAPTA-T 
of cells pre-treated with the Rho inhibitor, increases by 5-fold their capability to resist to the 
enzymatic action of trypsin, in comparison with the relevant controls. After the treatment with 
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this concentration, cells pre-treated with the inhibitor show a lower (- 40%) resistance to 
trypsin harvesting in comparison with the cells exposed only to RAPTA-T. The treatment 
with the highest concentration (i.e. 10-4 M) further increases, from a statistic point of view, the 
ability of pre-treated cells to adhere to collagen IV after trypsin exposure; this effect is 
detectable not only when compared to the relevant controls, but also when compared to 
controls not exposed to the inhibitor. 
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Figure 4.23. Effects of RAPTA-T on resistance to detachment after pre-treatment with a Rho inhibitor. MDA-
MB-231 and HBL-100 cells seeded 72 hours before on 96-well plastic plates previously coated with poly-L-
lysine, fibronectin and collagen IV, were exposed for 4 hours to a Rho inhibitor at 3µg/mL, then the solution 
with the inhibitor was discarded wells washed and cells were exposed for 1 hour to RAPTA-T 10-6, 10-5 and 10-
4
 M treatment and afterwards to a diluted trypsin solution for 30 minutes, before detecting cells still attached to 
the growth substrate by the SRB assay. Arbitrary units are calculated from the mean ± S.D. of two experiments, 
each performad in quadruplicate and controls are set equal to 1. ANOVA and Tukey Kramer post test.: bar 
labelled with the same letter are statistically different, a, b, c, d, e, **, P<0.01; f, P<0.05; §, P<0.05; §§§, 
P<0.001 versus controls not exposed to the inhibitor nor to RAPTA-T, on the same substrate, #, P<0.05; ###, 
P<0.001 versus controls pre-treated with inhibitor on the same substrate.  
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4.9 RAPTA-T effects on cell cytoskeleton after the inhibition of Rho GTPases 
The Rho inhibitor can interfere with cytoskeleton rearrangements, in an opposite way to 
that of RAPTA-T (see paragraph 4.7). For this reason it was evaluated if RAPTA-T still 
maintains its effect at this level after the treatment with the Rho inhibitor. 
When MDA-MB-231 cells are grown on poly-L-lysine (figure 4.24), the Rho inhibitor 
reduces actin organization and cellular spread; 10-6 M RAPTA-T seems to increase this effect 
by further reducing the amount of actin. At the two higher concentrations, RAPTA-T only 
partially counteracts the action of the inhibitor: in particular, there is more actin condensed 
under the plasmatic membrane. Moreover 10-4 M RAPTA-T increases cell spreading as 
compared to the inhibitor. The highly invasive cell line, grown on fibronectin (figure 4.25), 
shows the actin cytoskeleton better organized than cells grown on poly-L-lysine, with a 
consistent presence of stress fibres and cortical actin. The exposure to the tested Rho inhibitor 
causes a reduction of actin organization. After cell exposure to the inhibitor, RAPTA-T, either 
at the concentrations 10-6 or 10-4 M, weakly increases the amount of actin fibres; moreover 
cell protrusions are also augmented. On MDA-MB-231 cells, grown on collagen IV (figure 
4.26), the pre-treatment with the inhibitor has a strong effect: it causes a marked reduction of 
actin amount and of its organization. Among the treatment concentrations tested, only 10-5 M 
is able to revert the effects of the inhibitor, while the treatment at the highest concentration 
shows the ability to increase cell spreading. 
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MDA-MB-231 poly-L-lysine 
  CONTROLS     Rho INHIBITOR 
                                       
          RAPTA-T 10-6 M                               RAPTA-T 10-5 M                    RAPTA-T 10-4 M 
   
Figure 4.24. Effects of RAPTA-T treatment on cytoskeleton of cells pre-treated with a Rho inhibitor. MDA-
MB-231 cells seeded 72 hours before on poly-L-lysine, were exposed for 4 hours to a Rho inhibitor at 3µg/mL, 
then the solution with the inhibitor was discarded, wells washed and cells treated with RAPTA-T 10-6, 10-5 and 
10-4 M for 1 hour. At the end of the treatment cells were incubated with phalloidin Alexa-Fluor® 488 and 
antibody anti-paxillin. Images were acquired with a confocal system MRC-1024 using a Bio-Rad LaserSharp 
confocal software. Magnification 63X. 
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MDA-MB-231 fibronectin 
  CONTROLS    Rho INHIBITOR 
                                          
                RAPTA-T 10-6 M  RAPTA-T 10-5 M  RAPTA-T 10-4 M 
   
Figure 4.25. Effects of RAPTA-T treatment on cytoskeleton of cells pre-treated with a Rho inhibitor. MDA-
MB-231 cells seeded 72 hours before on fibronectin, were exposed for 4 hours to a Rho inhibitor at 3µg/mL, 
then the solution with the inhibitor was discarded, wells washed and cells treated with RAPTA-T 10-6, 10-5 and 
10-4 M for 1 hour. At the end of the treatment cells were incubated with phalloidin Alexa-Fluor® 488 and 
antibody anti-paxillin. Images were acquired with a confocal system MRC-1024 using a Bio-Rad LaserSharp 
confocal software. Magnification 63X. 
 81 
 
 
MDA-MB-231 collagen IV 
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                RAPTA-T 10-6 M  RAPTA-T 10-5 M  RAPTA-T 10-4 M 
   
Figure 4.26. Effects of RAPTA-T treatment on cytoskeleton of cells pre-treated with a Rho inhibitor. MDA-
MB-231 cells seeded 72 hours before on collagen IV, were exposed for 4 hours to a Rho inhibitor at 3µg/mL, 
then the solution with the inhibitor was discarded, wells washed and cells treated with RAPTA-T 10-6, 10-5 and 
10-4 M for 1 hour. At the end of the treatment cells were incubated with phalloidin Alexa-Fluor® 488 and 
antibody anti-paxillin. Images were acquired with a confocal system MRC-1024 using a Bio-Rad LaserSharp 
confocal software. Magnification 63X. 
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The pre-treatment of the non tumorigenic cell line, with the Rho inhibitor, induces a 
reduction of both the actin organization and quantity on all the substrates taken into 
consideration. After the exposure to the inhibitor, the treatment with RAPTA-T at the lowest 
concentration, of cells grown on poly-L-lysine (figure 4.27), increases only the amount of 
actin; regarding the other concentrations tested, only 10-4 M induces a detectable effect on cell 
morphology, specifically by increasing cell spreading. On HBL-100 cells sown on fibronectin 
(figure 4.28), and pre-treated with the inhibitor, RAPTA-T only weakly increases the amount 
of actin in comparison with the controls treated with the Rho inhibitor. On collagen IV (figure 
4.29), RAPTA-T, at the concentration of 10-6 M, does not change the inhibitory effect of C3 
transferase on the non tumorigenic cell line, while 10-5 M weakly increases the quantity of 
actin, and the highest concentration almost completely counteracts the effects of the inhibitor. 
The presence of focal contacts, which are detected with an anti-paxillin antibody, was 
not found in control cells nor in any of the treated cells. 
 
 
HBL-100 poly-L-lysine 
  CONTROLS     Rho INHIBITOR 
                                          
                RAPTA-T 10-6 M  RAPTA-T 10-5 M  RAPTA-T 10-4 M 
   
Figure 4.27. Effects of RAPTA-T treatment on cytoskeleton of cells pre-treated with a Rho inhibitor. HBl-100 
cells seeded 72 hours before on poly-L-lysine, were exposed for 4 hours to a Rho inhibitor at 3µg/mL, then the 
solution with the inhibitor was discarded, wells washed and cells treated with RAPTA-T 10-6, 10-5 and 10-4 M 
for 1 hour. At the end of the treatment cells were incubated with phalloidin Alexa-Fluor® 488 and antibody anti-
paxillin. Images were acquired with a confocal system MRC-1024 using a Bio-Rad LaserSharp confocal 
software. Magnification 63X. 
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HBL-100 fibronectin 
  CONTROLS     Rho INHIBITOR 
                                          
                RAPTA-T 10-6 M  RAPTA-T 10-5 M  RAPTA-T 10-4 M 
    
Figure 4.28. Effects of RAPTA-T treatment on cytoskeleton of cells pre-treated with a Rho inhibitor. HBL-100 
cells seeded 72 hours before on fibronectin, were exposed for 4 hours to a Rho inhibitor at 3µg/mL, then the 
solution with the inhibitor was discarded, wells washed and cells treated with RAPTA-T 10-6, 10-5 and 10-4 M 
for 1 hour. At the end of the treatment cells were incubated with phalloidin Alexa-Fluor® 488 and antibody anti-
paxillin. Images were acquired with a confocal system MRC-1024 using a Bio-Rad LaserSharp confocal 
software. Magnification 63X. 
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HBL-100 collagen IV 
  CONTROLS     Rho INHIBITOR 
                                         
                RAPTA-T 10-6 M  RAPTA-T 10-5 M  RAPTA-T 10-4 M 
   
Figure 4.29. Effects of RAPTA-T treatment on cytoskeleton of cells pre-treated with a Rho inhibitor. HBL-100 
cells seeded 72 hours before on collagen IV, were exposed for 4 hours to a Rho inhibitor at 3µg/mL, then the 
solution with the inhibitor was discarded, wells washed and cells treated with RAPTA-T 10-6, 10-5 and 10-4 M 
for 1 hour. At the end of the treatment cells were incubated with phalloidin Alexa-Fluor® 488 and antibody anti-
paxillin. Images were acquired with a confocal system MRC-1024 using a Bio-Rad LaserSharp confocal 
software. Magnification 63X 
 85 
4.10 Analysis of Rho A activation 
Among the Rho GTPases inhibited by C3 transferase (RhoA, RhoB and RhoC), the 
protein mainly studied for its influences on cytoskeleton rearrangement is RhoA, which is 
predominantly involved in stress fibres and focal contact formation. We therefore investigated 
more in detail the effects of RAPTA-T on RhoA.  
To measure the effect of RAPTA-T on the activation of RhoA, on MDA-MB-231 and 
on HBL-100 cells seeded on plates coated with fibronectin, collagen IV and poly-L-lysine, an 
appropriate kit (described in paragraph 3.16) was used. The effects of an activator of RhoA 
(Cytochalasin D) and of a Rho inhibitor (C3 transferase, linked to a proprietary cell 
penetrating moiety), in the highly invasive cell line (figure 4.30, upper panel), are substrate 
dependent. The activation enhanced by Cytochalasin D is strong when cells are grown on 
poly-L-lysine (+70% versus controls) and on fibronectin (+60% versus controls), whereas it is 
less pronounced (+30% versus controls) if collagen IV is used as growth substrate. Similar 
considerations can be drawn for the activity of the Rho inhibitor, of which shows an efficacy 
more evident in cells grown on collagen IV (-40% versus controls), then in cells grown on 
poly-L-lysine (-25% versus controls); it is virtually inactive (-6% versus controls) in cells 
sown on fibronectin. In the case of the inhibitor, it should be highlighted that it is not selective 
for RhoA only, but it acts on all the three isoforms of this GTPases family. On the MDA-MB-
231 cells grown on poly-L-lysine, RAPTA-T increases RhoA activation at all concentrations 
and expecially at 10-5 M (+ 30% versus controls). On MDA-MB-231 cells grown on 
fibronectin, RAPTA-T is moderately (+15% versus controls) effective only in inducing RhoA 
activation at 10-5 M, whereas the other two concentration do not affect the activation of this 
protein. On cells grown on collagen IV there are different effects: the lowest concentration 
increases the activated RhoA by 30% (similarly to the positive control Cytochalasin D); 10-
5M reduces by the same amount the active protein, and the highest concentration has an 
irrelevant effect. 
On the non tumorigenic cell line (figure 4.30, lower panel), considerations similar to 
those reported above for the invasive cell line, can be done on the effect of the activator and 
of the inhibitor. The inhibitor always gives a marked reduction, figure 4.30 (lower panel), 
ranging from - 50% versus controls on poly-L-lysine, to - 70% versus controls on fibronectin 
and collagen IV. The effect of Cytochalasin D is maximal in cells grown on poly-L-lysine (+ 
50% versus controls), medium (+ 30% versus controls) in cells sown on fibronectin, and 
practically absent in cells on collagen IV (+ 7% versus controls). Looking at the effects of 
RAPTA-T, a general reduction of RhoA activation can be observed independently of the 
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substrate of growth. In some cases, as on fibronectin, this reduction of RhoA activation is 
proportional to the concentration used. 
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Figure 4.30. Effects of RAPTA-T on RhoA activation. MDA-MB-231 and HBL-100 cells were sown 72 hours 
before on 6-well plastic plates previously coated with poly-L-lysine, fibronectin and collagen IV. Negative 
controls are obtained exposing the cells for 4 hour to a Rho inhibitor at 3µg/mL, as positive controls cells were 
exposed for 1 hour to Cytochalasin D at 2µg/mL. The samples used to determine the effect of RAPTA-T 
treatment were exposed for 1 hour to RAPTA-T 10-6, 10-5 and 10-4 M. At the end of the treatments cells were 
lysated, and the protein lysate was used to measure RhoA activation. Data showed in graph are calculated from 
the mean ± S.D. of two experiments, each performed in duplicate and controls are set equal to 100%, represented 
as a line on the graph.  
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4.11 Determination of ruthenium associated with the cells and the substrates 
To evaluate if the effects of RAPTA-T treatment, described on cytoskeleton 
remodelling (paragraph 4.7) and on resistance to detachment (paragraph 4.1 and 4.8), could be 
ascribed to its association with the cells or with the substrates, the capability of RAPTA-T to 
bind to the cells and to the substrates was determined by atomic absorption spectroscopy 
(AAS). MDA-MB-231 and HBL-100 cells grown on poly-L-lysine, fibronectin and collagen 
IV were exposed to a treatment with 10-6, 10-5, 10-4 M RAPTA-T. The same concentrations 
were used to treat the substrates alone, to evaluate if and how they could influence the uptake 
of the compound by the cells. 
The association of the compound with the cells and with the substrates is expressed as 
micrograms of ruthenium per millilitre, assuming that 106 cells correspond approximately to 1 
µL and supposing density being equal to 1 g/mL.  
After treatment for 1 hour with RAPTA-T at the concentration 10-5 M the association of 
ruthenium with cells does not change in relation with the growth substrate, but there is more 
ruthenium associated to the highly invasive cell line than to the non tumorigenic one (figure 
4.31). The differences in ruthenium uptake by the two cell lines (figure 4.31), becomes more 
evident, and statistically significant, after treatment with 10-4 M: ruthenium associated with 
MDA-MB-231 is 5 times higher than that associated with HBL-100. Moreover ruthenium 
uptake by MDA-MB-231 cells, treated with RAPTA-T at 10-4 M, is increased when cells are 
grown on ECM components than on poly-L-lysine. After treatment with 10-6 M RAPTA-T 
ruthenium bound to the cells is below the threshold of detection. 
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Figure 4.31 Ruthenium uptake, in MDA-MB-231 (left panel) and HBL-100 cells (right panel). Cells were 
seeded on plastic plates 100·20 mm previously coated with poly-L-lysine, fibronectin and collagen IV, then 
treated for 1 hour with RAPTA-T 10-6, 10-5 and 10-4 M. At the end of the treatment cells were harvested and 
counted and the concentration of ruthenium was determined by AAS. Data are mean ± S.D. of two experiments, 
each performed in triplicate. ANOVA and Tukey Kramer post test: *: P < 0.05 ***: P < 0.001 10-5 M vs 10-4 M 
in cells grown on the same substrate, ###, P < 0.001 MDA-MB-231 vs HBL-100.  
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The analysis of the ruthenium associated to the substrates alone and to the substrates on 
which cells have been sown, shows that RAPTA-T, in the presence of the cells, binds mainly 
the cells and not the substrates. As shown in figure 4.32, there is significantly less ruthenium 
bound to the substrates, on which cells are grown, in comparison with the substrates alone. 
Looking at the differences between the two cell lines, it is evident that ruthenium association 
with the substrates on which MDA-MB-231 cells are grown, is always higher, at least twice 
as much, than that associated to the substrates on which HBL-100 are grown. The 
approximately double ruthenium concentration bound to ECM proteins, in comparison to 
poly-L-lysine, underlines a preference of the compound for ECM proteins. 
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Figure 4.32. Ruthenium association with poly-L-lysine, fibronectin and collagen IV alone or under cells. Plastic 
plates 100·20 mm previously coated with poly-L-lysine, fibronectin and collagen IV were treated for 1 hour with 
RAPTA-T 10-6, 10-5 and 10-4 M, at the end of the treatment the plates were kept in contact with of 
tetramethylammonium hydroxide, then the solutions were collected and the ruthenium content was determinated 
by AAS. To collect substrates under the cells, after cell harvesting the plates were kept in contact with of 
tetramethylammonium hydroxide as described above. Data are mean ± S.D. of two experiments, each performed 
in triplicate. §, P < 0.05, substrate alone: poly-L-lysine vs fibronectin both treated with RAPTA-T 10-4M ;***, P 
< 0.001 substrate alone: poly-L-lysine treated with RAPTA-T 10-5M vs poly-L-lysine treated with RAPTA-T 10-
4M; #, P < 0.05; ##, P < 0.01; ###, P < 0.001: substrate alone vs substrate under cells both treated with RAPTA-
T 10-4M. ANOVA and Tukey Kramer post test. 
 
To further investigate ruthenium uptake, the kinetics of the uptake after RAPTA-T 
treatment was analysed. For this purpose the uptake of ruthenium, in the same conditions 
previously considered (cells, substrates alone and with cells), was measured after a treatment 
of 15, 30 and 60 minutes at 10-4 M.  
Looking at the ruthenium uptake by the cells seeded on poly-L-lysine (figure 4.33), it 
increases on MDA-MB-231 cells after 60 minutes of treatment, in comparison with the 
shorter treatments of 15 and 30 minutes. In HBL-100 cells, the ruthenium uptake increases, as 
a function of treatment length, is much less pronounced. 
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Figure 4.33. Time course of ruthenium uptake by poly-L-lysine, MDA-MB-231 and HBL-100 cells. Cells 
seeded 72 hours before on plastic plates 100·20 mm previously coated with poly-L-lysine, were treated for 15, 
30 and 60 minutes with RAPTA-T 10-4 M. At the end of the treatment, cells were harvested and counted and the 
concentration of ruthenium was determined by AAS. For the determination of ruthenium bound to the poly-L-
lysine, plastic plates 100·20 mm previously coated with poly-L-lysine were treated for 15, 30 and 60 minutes 
with RAPTA-T 10-4 M, at the end of the treatment plates were kept in contact with tetramethylammonium 
hydroxide, then the solutions were collected and the ruthenium content was determined. Data are mean ± S.D. of 
two experiments, each performed in triplicate. ANOVA and Tukey Kramer post test: **, P < 0.01; ***, P < 
0.001 between the substrate alone and the substrate under HBL-100. 
 
The comparison of data of figures 4.33, 4.34 and 4.35 shows that ruthenium cellular 
uptake is dependent on the time of exposure for the highly invasive cell line only. Moreover, 
the time-exposure dependence of ruthenium uptake in MDA-MB-231 cells is much more 
evident on ECM components than on the non specific cell adhesion substrate poly-L-lysine. 
The different uptake detected on the two cell lines grown on fibronectin (figure 4.34) starts to 
be appreciable after a treatment of 30 minutes, and, 60 minutes later, ruthenium associated 
with the MDA-MB-231 cells is 4 times higher than that associated with HBL-100 cells, 
(statistically significant difference). 
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Figure 4.34. Time course of ruthenium uptake by fibronectin, MDA-MB-231 and HBL-100 cells. Cells seeded 
72 hours before on plastic plates 100·20 mm previously coated with fibronectin, were treated for 15, 30 and 60 
minutes with RAPTA-T 10-4 M. At the end of the treatment, cells were harvested and counted and the 
concentration of ruthenium was determined by AAS. For the determination of ruthenium bound to the 
fibronectin, plastic plates 100·20 mm previously coated with fibronectin were treated for 15, 30 and 60 minutes 
with RAPTA-T 10-4 M, at the end of the treatment plates were kept in contact with tetramethylammonium 
hydroxide, then the solutions were collected and the ruthenium content was determined. Data are mean ± S.D. of 
two experiments, each performed in triplicate. ANOVA and Tukey Kramer post test: **, P < 0.01; ***, P < 
0.001 between substrate alone and substrate under HBL-100; ### P < 0.001 between substrate alone and 
substrate under MDA-MB-231; §, P < 0.05; §§§, P < 0.001 vs respective 60’ treatment; b P < 0.001 between 
MDA-MB-231 and HBL-100.  
 
MDA-MB-231 cells seeded on collagen IV and treated with 10-4 M RAPTA-T, show a 
different kinetics of uptake, compared to the same cells grown on fibronectin: as shown in 
figure 4.35 cellular uptake significantly increases (more than twice) from 15 to 30 minutes of 
treatment, whereas between 30 and 60 minutes only a weaker increase of the uptake is 
measured. 
Comparing the ruthenium bound to the substrates, there are no modifications related to 
the exposure time, when substrates are collected immediately after cell removal; on the 
contrary, on substrates alone the selectivity of the compound towards ECM components is 
confirmed: as shown in figures 4.34 and 4.35, there is a significant increase related with the 
time of exposure to RAPTA-T only on fibronectin and collagen IV; after 60 minutes of 
treatment, the ruthenium associated to the substrates is at least twice higher than after 15 
minutes.  
 
 91 
COLLAGEN IV
15' 30' 60'
0.0
0.1
0.2
10
20
30
40
50
collagen IV
collagen IV u/MDA-MB-231
collagen IV u/HBL-100
MDA-MB-231 on collagen IV
HBL-100 on collagen IV
µ g
 
Ru
/m
L
time
§
*
§§
a
b
 
Figure 4.35. Time course of ruthenium uptake by collagen IV, MDA-MB-231 and HBL-100 cells. Cells seeded 
72 hours before on plastic plates 100·20 mm previously coated with collagen IV, were treated for 15, 30 and 60 
minutes with RAPTA-T 10-4 M. At the end of the treatment, cells were harvested and counted and the 
concentration of ruthenium was determined by AAS. For the determination of ruthenium bound to the collagen 
IV, plastic plates 100·20 mm previously coated with collagen IV were treated for 15, 30 and 60 minutes with 
RAPTA-T 10-4 M, at the end of the treatment plates were kept in contact with tetramethylammonium hydroxide, 
then the solutions were collected and the ruthenium content was determined. Data are mean ± S.D. of two 
experiments, each performed in triplicate. ANOVA and Tukey Kramer post test: *, P < 0.05 between substrate 
alone and substrate under HBL-100; §, P < 0.05,§§, P < 0.01 vs respective 60’ treatment; a, P < 0.05; b P < 0.001 
between MDA-MB-231 and HBL-100.  
 
4.12 Effects of pre-treatment of the substrates on cell adhesion 
AAS data described above, showed that RAPTA-T binds to the substrates, in particular 
to the ECM proteins, fibronectin and collagen IV. The following experiment was planned 
with the aim to evaluate if RAPTA-T bound to the substrates could interfere with the 
adhesion of cells. For this purpose the substrates were exposed, for 1 hour to 10-6, 10-5, 10-4M 
RAPTA-T, before seeding the cells. As shown in figure 4.36, upper panel, the ability of 
MDA-MB-231 cells to adhere to fibronectin and to collagen IV, pre-treated with RAPTA-T, 
increases by 20% in comparison to the same unexposed control substrate. The effect is 
independent on the concentration used and, despite these results are not statistically 
significant, they sound interesting because on poly-L-lysine no such effects are detected. 
In the lower panel of figure 4.36, the different behaviour of HBL-100 cells, whose 
adhesion ability is increased on collagen IV only, where the effect seems to be concentration-
dependent, is clearly evident. No such effects are detectable on fibronectin or on poly-L-
lysine. 
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Figure 4.36. Effects on ability of cells to adhere after RAPTA-T treatment of the substrates. 96 well plastic 
plates previously coated with poly-L-lysine, fibronectin, collagen IV were treated with the compound for 1 hour 
at the concentration of 10-6, 10-5 and 10-4 M, at the end of the treatment MDA-MB-231 and HBL-100 cells were 
removed from the flasks, collected, resuspended and seeded on the plates. After 1 hour of incubation cells that 
adhered to the substrates were detected by the SRB assay. Data are the percent of controls calculated from the 
mean ± S.D. of two experiments, each performed in triplicate. 
4.13 Interactions of RAPTA-T with substrates 
As a collaboration within the COST D39 consortium, some experiments were 
performed to analyse the interaction of RAPTA-T with substrates, by studying the hydrolysis 
of the ruthenium compound over 5 hours by 31P NMR in water and the hydrolysis over 1 hour 
by 31P NMR in DPBS buffer, in the presence of the different substrates. 
In water the hydrolysis is faster than in DPBS (figure 4.37 and figure 4.38); the rate of 
hydrolysis (estimated by integration of hydrolysed to unhydrolysed compound) was different 
for different substrates: hydrolysis in presence of poly-L-lysine was a bit faster (20-25%) in 
comparison to the experiment done with fibronectin. In contrast to what happens with poly-L-
lysine and fibronectin, the addition of the collagen IV to the RAPTA-T solution leads to the 
formation of new species (peaks between 26 and 30 ppm), rather than influence the rate of 
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hydrolysis. In the laboratory of Prof. P.J. Dyson at the EPFL (Switzerland) it was not possible 
to identify what kind of products are formed, but they supposed they were complexes between 
collagen IV and RAPTA-T: the appearance of three new signals could be attributed to the 
formation of complexes between collagen IV and RAPTA-T derivatives with a different 
number of chlorido ligands. 
 
NMR analysis in water 
 
Products of interaction with collagen IV 
 
 
Figure 4.37 Interactions of RAPTA-T with substrates (poly-L-lysine, collagenIV, fibronectin) detected with 
NMR. 0.6 mg RAPTA–T were solubilised in mixture (0.6 mL of substrate solution + 0.1 mL of D2O). 31P NMR 
spectra were recorded in 20 minutes after mixing. For experiment in water 31P NMR was recorded also after 5 
hours. 
The addition of DPBS fully suppresses hydrolysis (figure 4.38), and no hydrolysis 
products were observed even after 5 hours. The NMR analysis of RAPTA-T solubilised in 
DPBS buffer with the addition of the substrates, shows a small increase of the hydrolysis rate 
when RAPTA-T is incubated with poly-L-lysine or fibronectin. Between these two substrates 
no differences and no further hydrolysis are detected. As still observed in water solution, the 
addition of collagen IV to the solution of RAPTA-T in DPBS, has an effect different from 
that observed with poly-L-lysine and fibronectin. The presence of collagen IV leads to the 
formation of conjugates with the protein (peaks between 26 and 30 ppm) and no hydrolytical 
degradation is detected. It seems that the products which are formed after the addition of 
collagen IV to the RAPTA-T solution in DPBS are different from the products observed in 
water solution. 
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NMR analysis in DPBS 
 
Products of interaction with collagen IV 
 
Figure 4.38 Interactions of RAPTA-T with substrates (poly-L-lysine, collagenIV, fibronectin) detected with 
NMR. 0.6 mg RAPTA–T were solubilised in mixture (0.4 mL of substrate solution + 0.2 mL of DPBS + 0.1 mL 
of D2O). 31P NMR spectra were recorded 20 minutes after mixing. For experiment in water 31P NMR was 
recorded also after 5 hours. 
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4.14 Immunocytochemistry 
The effects of RAPTA-T treatment on β1 integrin activation on the membrane of MDA-
MB-231 cells was analysed with an immunocytochemistry technique. On MDA-MB-231 
cells, seeded on poly-L-lysine, RAPTA-T treatment induces the activation of β1 integrin at 
10-6M only, as indicated in figure 4.39. Considering RAPTA-T effects on cells grown on 
ECM components, RAPTA-T treatment induces the activation of the subunit β1 on cells 
grown on fibronectin only (figure 4.40) and this effect seems to be dose dependent. On the 
contrary cells grown on collagen IV do not show any integrin activation, but they undergo an 
evident change in their morphology: the compound induces cells to extend filopodia and to 
acquire a spread phenotype, that is more pronounced after the treatment with the 
concentration 10-5 and 10-6 M (as indicated in figure 4.41).  
 
MDA-MB-231 
Poly-L-lysine 
CONTROLS                                         RAPTA-T 10-6 M 
    
RAPTA-T 10-5 M                                RAPTA-T 10-4 M 
    
Figure 4.39. Effects of RAPTA-T on β1 integrin activation. MDA-MB-231 cells, seeded 72 hours before on 
poly-L-lysine, were treated with RAPTA-T 10-6, 10-5 and 10-4 M for 1 hour. At the end of the treatment cells 
were incubated with an antibody anti-β1 active. Images were acquired with a light microscope (Orthoplan, Leitz, 
Germany) with magnification 800X.  
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Figure 4.40. Effects of RAPTA-T on β1 integrin activation. MDA-MB-231 cells, seeded 72 hours before on 
fibronectin, were treated with RAPTA-T 10-6, 10-5 and 10-4 M for 1 hour. At the end of the treatment cells were 
incubated with an antibody anti-β1 active. Images were acquired with a light microscope (Orthoplan, Leitz, 
Germany) with magnification 800X.  
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Figure 4.41. Effects of RAPTA-T on β1 integrin activation. MDA-MB-231 cells, seeded 72 hours before on 
collagen IV, were treated with RAPTA-T 10-6, 10-5 and 10-4 M for 1 hour. At the end of the treatment cells were 
incubated with an antibody anti-β1 active. Images were acquired with a light microscope (Orthoplan, Leitz, 
Germany) with magnification 800X.  
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4.15 Effects of RAPTA-T on cell detachment immediately after adherence 
This assay is used to evaluate the effects of RAPTA-T on cells immediately after they 
adhered to the substrate, i.e. when only the first adhesion molecules (like for example 
integrins) had been engaged in the adhesion process. The treatment of the highly invasive cell 
line with RAPTA-T is in general able to counteract trypsin mediated detachment. On poly-L-
lysine (figure 4.42, upper panel) the effect is influenced by the high variability of the samples. 
Conversely on cells adhered on ECM components, 10-4 M RAPTA-T increases, in a 
statistically significant way, the ability of the cells to resist to the action of the enzyme. The 
effect is particularly pronounced on cells on collagen IV where it is quantitatively more 
relevant than on fibronectin. On the non tumorigenic HBL-100 cells (figure 4.42, lower panel) 
RAPTA-T treatment, at 10-5 and 10-4 M concentrations, significantly increases the number of 
cells adherent to the substrate after trypsin exposure, only when they are seeded on collagen 
IV. 
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Figure 4.42. Effects of RAPTA-T on resistance to detachment. MDA-MB-231 and HBL-100 cells were seeded 
1 hour before on 96-well plastic plates previously coated with poly-L-lysine, fibronectin and collagen IV, 
exposed for 1 hour to the compounds 10-6, 10-5 and 10-4 M and then to a diluted trypsin solution for 30 minutes, 
before detecting cells still attached to the growth substrate by the SRB assay. Arbitrary units are calculated from 
the mean ± S.D. of two experiments, each performad in quadruplicate and controls are set equal to 1. ANOVA 
and Tukey Kramer post test: ***: P<0.001 versus controls.  
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4.16 Detection of α1β1 integrin 
Integrins are among the molecules first and mainly involved in the regulation of cell-
matrix interactions, moreover they activate some signals, through the involvement of Rho 
GTPases, directly related with cytoskeleton rearrangements. On these basis the possible 
interaction between RAPTA-T and integrins was evaluated, in particular with the collagen IV 
- binding integrin α1β1. Before this analysis, the expression of the α1β1 integrin on the 
surface of MDA-MB-231 and HBL-100 cells was detected using flow cytometry. As shown 
in figure 4.43 and 4.44 (right panel) the whole population in both cell lines expresses the β1 
integrin chain detected using a rabbit polyclonal antiserum against the β1 subunit and, as 
secondary antibody, an anti-rabbit IgG Alexa Fluor 647-R-phycoeritrin. On the contrary, the 
α1 chain, detected with a primary murine monoclonal antibody followed by a secondary 
antibody anti-mouse IgG R- phycoeritrin, is not expressed by the highly invasive cell line 
MDA-MB-231 (figure 4.43, left panel), while the non tumorigenic HBL-100 (figure 4.44, left 
panel) cell line expresses α1 subunit in 100% of cell population. 
 
 
MDA-MB-231 
 
Figure 4.43. Expression of α1β1 integrin on the surface of MDA-MB-231 cells. Cells were incubated with 5 
µg/mL primary antibody anti α1 or  with a rabbit polyclonal antiserum against the human β1 integrin. Then cells 
were washed and incubated with a secondary antibody R-phycoerytrin goat anti-mouse IgG 1:500, or with the 
same concentration of a goat anti-rabbit IgG Alexa Fluor 647-R-phycoeryhrin respectively for detection of α1 or 
β1 integrin chains. Samples were analysed with the flow cytometer (Partec). Controls are represented by the red 
area, the black line represent the expression of the β1 subunit and the blue line represent the expression of the α1 
subunit.  
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HBL-100 
 
 
Figure 4.44. Expression of α1β1 integrin on the surface of HBL-100 cells. Cells were incubated with 5 µg/mL 
primary antibody anti α1 or  with a rabbit polyclonal antiserum against the human β1 integrin. Then cells were 
washed and incubated with a secondary antibody R-phycoerytrin goat anti-mouse IgG 1:500, or with the same 
concentration of a goat anti-rabbit IgG Alexa Fluor 647-R-phycoeryhrin respectively for detection of α1 or β1 
integrin chains. Samples were analysed with the flow cytometer (Partec). Controls are represented by the red 
area, the black line represent the expression of the β1 subunit and the blue line represent the expression of the α1 
subunit.  
 
4.17 Detection of ruthenium bound to integrins 
As a collaboration within the COST D39 consortium, some experiments were 
performed at the University of Frankfurt to analyse the interaction between integrin α1β1 and 
RAPTA-T. Figure 4.45 represents the absorbance at 254 nm, detecting the type of proteins in 
the eluate of a gel filtration column: the peak at 10 minutes represent the integrin eluted. The 
detection of Ru2+ present in the eluate of the gel filtration column was performed using ICP-
MS detection; as shown in figure 4.46 the peak at 10 minutes in the early (high molecular 
weight) fraction of the gel filtration eluate represents Ru2+ associated with the integrin, and it 
corresponds to the peak of the figure 4.45. In figure 4.46 the peak at 25 minutes is the 
ruthenium in the low molecular weight fraction of the gel filtration eluate, and it corresponds 
to RAPTA-T alone, i.e. not bound to the integrin. 
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Figure 4.45 Detection of protein present in the eluate of a gel filtration column. 10-4 M RAPTA-T was added to 
an integrin-solution (ratio RAPTA-T : integrin, ca 20:1) and incubated overnight at 37°C. Then, the sample was 
applied to a sephadex200 gel filtration column and eluted in 100 mM ammonium acetate buffer, pH. 7.4. The 
integrin is detected by absorption at 245 nm.  
 
 
Figure 4.46 ICP-MS detection of Ru2+ ion concentration in the eluate of a gel filtration column. 10-4 M 
RAPTA-T was added to an integrin-solution (ratio RAPTA-T : integrin, ca 20:1) and incubated overnight at 
37°C. Then, the sample was applied to a sephadex200 gel filtration column and eluted in 100 mM ammonium 
acetate buffer, pH. 7.4. The eluate of the gel filtration column was immediately injected to the ICP-MS detection 
in order to quantify the Ru2+-ion concentration. 
4.18 Binding of α1β1 integrin with collagen IV 
The RAPTA-T capability to interfere with the binding of α1β1 to its natural ligand 
collagen IV, was evaluated in a cell-free system using an ELISA assay and, in parallel at 
cellular level, using the cell adhesion assay in which cells are treated in suspension. Data of 
(figure 4.47) show the metal compound free of influence on the binding of the α1β1 integrin 
to collagen IV: in fact the curve of integrin – collagen IV interaction in the presence of 10-4 M 
RAPTA-T is practically identical to the curve obtained in the absence of the metal compound. 
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Figure 4.47. Integrinic binding. An ELISA assay was used to evaluate the capability of RAPTA-T 10-4 M 
treatment to interfere with the binding of α1β1 integrin with collagen IV, its natural ligand, on 96 well plates 
previously coated with collagen IV. Integrin bound with the substrate after the treatment was detected using 
rabbit polyclonal antiserum against the human β1 and a secondary anti rabbit conjugated to alkaline phosphatase. 
 
This result is confirmed by the analysis at cellular level: MDA-MB-231 and HBL-100 
were seeded on 96 well plates previously coated with collagen IV, and during the 1 hour 
adhesion process cells were kept in contact with 10-6, 10-5, 10-4 M RAPTA-T. As shown in 
figure 4.48 these treatments have only weak effects, probably biologically irrelevant, on the 
capability of both cell lines to adhere to collagen IV. 
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Figure 4.48. Effects on the ability of cells to adhere to collagen IV during RAPTA-T treatment. MDA-MB-231 
and HBL-100 cells grown for 72 hours on flasks, were removed from the support, collected, resuspended in a 
solution of RAPTA-T  at the concentrations of 10-6, 10-5 and 10-4 M and seeded on 96 well plastic plates 
previously coated with collagen IV. After 1 hour of incubation cells that are adherent to the substrate were 
detected by the crystal violet assay. Data on graph are calculated from the mean ± S.D. of two experiments each 
performed in quadruplicate and controls are set equal to 1. 
 
The morphological analysis of cells that adhered to collagen IV (pictures of figure 4.49, 
lower panel right) shows that 10-4 M RAPTA-T increases cell spreading of MDA-MB-231 
cells, and induces the extension of cellular protrusions on the non tumorigenic cell line HBL-
100 at all concentrations used (figure 4.50). 
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Figure 4.49. Effects of the treatment in cell morphology on cells treated with RAPTA-T 10-6, 10-5 and 10-4 M 
during the adhesion process. MDA-MB-231 cells were removed from flasks, collected, resuspended in a solution 
of RAPTA-T and seeded on 96 well plastic plates previously coated with collagen IV. After 1 hour of incubation 
cells that are adherent to the substrate were stained with crystal violet.Acquisition performed with Olympys K71 
software MetaVue™ imaging sytem with magnification 220X. 
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Figure 4.50. Effects of the treatment in cell morphology on cells treated with RAPTA-T 10-6, 10-5 and 10-4 M 
during the adhesion process. HBL-100 cells were removed from flasks, collected, resuspended in a solution of 
RAPTA-T and seeded on 96 well plastic plates previously coated with collagen IV. After 1 hour of incubation 
cells that are adherent to the substrate were stained with crystal violet.Acquisition performed with Olympys K71 
software MetaVue™ imaging sytem with magnification 220X. 
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5 DISCUSSION 
The investigation of metal-based compounds, as potential drugs in cancer 
chemotherapy, is largely based on the knowledge derived from the clinical success of the 
platinum analogues cisplatin, carboplatin, and oxaliplatin (Kelland, 2007). The search of 
innovative metal-based drugs is focussed on the identification of possible advantages deriving 
from the use of metals different from platinum; in particular, ruthenium compounds have 
attracted a great interest and resonance, since two of them, NAMI-A (Rademaker-Lakhai et 
al, 2004) and KP1019 (Hartinger et al, 2006), gained a discrete success in preclinical 
experimental models, allowing them to enter in clinical trials. NAMI-A is characterized by a 
selective activity towards tumour metastases, largely demonstrated in different in vivo models 
of experimental tumours and of human xenografts, in which it is able to reduce the formation 
and growth of secondary lesions (Sava et al, 1998; Sava et al, 1999; Sava et al, 2003). This 
peculiar in vivo activity of NAMI-A is related with its ability to interfere with several steps of 
the metastatic process, as detected in in vitro models of cellular detachment (Sava et al, 2004; 
Frausin et al, 2004), invasion (Zorzet et al, 2000) and gelatinolytic activity (Sava et al, 1996; 
Vacca et al, 2002; Sava et al, 2003). KP1019 possesses an interesting anti-tumour activity 
toward autochthonous colorectal tumours of the rat (Keppler et al, 1989), more pronounced 
than that of 5-fluorouracil, the drug presents in virtually all chemotherapy regimens today 
used to treat colorectal cancer (Mamounas et al, 1999). It is noteworthy that NAMI-A and 
KP1019, two heterocyclic compounds, structurally very similar, display a marked different 
activity. One possible explanation of their different pharmacological behaviour relays on the 
presence of dimethylsulfoxide in the NAMI-A molecule, that confers it a reduction potential 
much more accessible to the hypoxic milieu of solid tumours, than that of KP1019, rendering 
NAMI-A easily reducible, by biological reductants such as ascorbic acid and gluthathione, to 
the corresponding ruthenium(II) compound (Alessio et al, 1993; Alessio et al, 2004; Schluga 
et al, 2006). 
The search of drugs active towards metastatic lesions is an open field and an urgent 
need of cancer chemotherapy, although still today there are very few drugs specifically 
designed to hinder this phenomenon. A ‘pure’ anti-metastatic drug should possess features 
different from that of traditional anti-tumour drugs, mainly selected by test mimicking their 
ability to inhibit the growth of primary tumours. In fact, tumour and metastatic cells have 
some fundamental distinct features (Christofori, 2006; Steeg, 2006): the ability to live without 
the contact with the neighbouring cells and with the microenvironment of the tissue of origin 
tissue, to invade foreign tissues, and to migrate toward distant organs are characteristics not 
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necessary for tumour cells, while they are essential for metastatic cells. For these reasons the 
first aim of this work was to set up and validate a model, constituted by a series of functional 
tests which mimic in vitro some relevant steps of the metastatic progression (i.e. cell 
detachment from the primary tumour, migration, invasion, and re-adhesion to a new growth 
substrate), to the study, identificate and select of molecules endowed of selective activity 
against the metastasis of solid tumours. The model is completed by the use of a couple of 
human cell lines endowed with different degree of tumorigenic and invasive potential: the 
highly invasive breast cancer cell line MDA-MB-231 (Cailleau et al, 1974) and the non 
tumorigenic mammary cell line HBL-100 (Gaffney, 1982). The individuation of drugs, with 
potentially selective anti-metastatic activity, could benefit from the differential behaviour of 
the test compounds in these two cell lines. To carry out the screening, some metal-based 
compounds were carefully chosen to allow a structure-activity relationship analysis, assuming 
NAMI-A, HIm[Ru(III)Cl4Imdmso], as a reference of an anti-metastatic molecule. To obtain 
variations of the chemical structure of NAMI-A the choice fell on two heterocyclic 
compounds, KP1019, HInd[Ru(III)Cl4(Ind)2], and KP418, HIm[Ru(III)Cl4(Im)2], 
characterized by two axial N-donor ligands, respectively indazole and imidazole, in place of 
the imidazole and of the dimethylsulfoxide present in the NAMI-A molecule. In parallel, 
thanks to the intriguing properties showed by RM175, [(η6-biphenyl)Ru(II)-
Cl(ethylendiamine)]PF6, in experimental tumour models (Morris et al, 2001), such as an in 
vitro cytotoxicity equipotent to carboplatin (Aird et al, 2002) and the absence of cross-
resistance with cisplatin (Aird et al, 2002), some organometallic compounds were included. 
Research on organometallics is a growing field of the inorganic chemistry, especially active in 
the study of Ru(II) arene complexes, a class of compounds exhibiting an altered profile of 
biological activity, in comparison with metal-based anticancer complexes currently in clinical 
use or in clinical trials (Chen et al, 2002; Chen et al, 2003; Liu et al, 2006). Some of these 
differences may be explained by the fact that these compounds have the ruthenium at the +2 
oxidation state, more reactive than ruthenium +3, and for this reason believed to be the active 
form of these drugs (Clarke, 2003). Besides RM175, the isostructural AFAP51, [(η6-
biphenyl)Os(II)Cl-(ethylendiamine)]BF4, was taken into consideration because it differs from 
the previous compound for the metal, with the metal centre being osmium instead of 
ruthenium, and allowing to determine the role of the central metal ion in the activity of these 
compounds. The set of five drugs is completed by RAPTA-T, [RuCl2(η6-toluene)PTA], 
belonging to the RAPTAs family of organometallics compounds, characterized by the 
presence of the PTA ligand (PTA = 1,3,5-triaza-7-phosphoadamantane), which seems to 
confer the interesting feature to be activated, by protonation, at the low pH typical of solid 
 105 
tumour cells (Allardyce et al, 2001; Allardyce et al, 2003). RAPTA-T was chosen, among 
other members of the RAPTA family, because of its differential cytotoxicity displayed against 
the TS/A adenocarcinoma cells (IC50= 74µM), whereas it is essentially non-toxic, up to 300 
µM, in the HBL-100 non tumorigenic cells (Scolaro et al,2005; Scolaro et al,2006). 
The first step of the metastatic progression is represented by the detachment of the 
tumour cells from the primary mass, and from its microenvironment. The analysis of the 
effects of the treatment with the test metal compounds shows that, despite the differences in 
the chemical structure, the activity of all the ruthenium compounds has a common trait, that is 
the ability to reduce the detachment, mainly on the highly invasive cell line. On the contrary, 
the osmium compound AFAP51 acts on the non tumorigenic cell line only, increasing its 
ability to adhere on poly-L-lysine, and decreasing this ability when cells are grown on ECM 
components. This result points out the relevance of the metal centre in influencing the activity 
of compounds on cancer cell detachment. A more detailed analysis of the effects of ruthenium 
compounds highlights the specificity of some of them to predominantly act when cells are 
grown on a particular substrate; the activity of KP418 is more pronounced when the cells are 
grown on fibronectin, and RAPTA-T induces a greater increase of the resistance to 
detachment when the highly invasive cells are sown on collagen IV and on fibronectin. 
Notably, the importance of the substrate to inhibit cell detachment evidenced with RAPTA-T 
is a feature shared with NAMI-A (Frausin et al, 2004). On the contrary, KP1019 and RM175 
act without displaying peculiar specificity to any of the growth substrates. 
The evaluation of the migratory ability of the treated cells, in response to a chemical 
(chemotaxis) or a contact (haptotaxis) stimulus, shows that similar compounds may possess 
very different effects. Considering the heterocyclic compounds, KP418 is completely devoid 
of effects in both migration tests, while KP1019 is the compound with the strongest activity, 
reducing cell migration in chemotaxis and haptotaxis, irrespectively of the invasive 
characteristics of the cell line. The organometallic compound RM175 mainly hinders 
haptotactic migration in both cell lines, whereas the osmium congener inhibits chemotaxis 
only. Similarly to what reported above, also in these tests, RAPTA-T is the only compound 
selectively affecting cell ability to migrate of the highly invasive cell line, and this is true 
independently of the nature of the stimulus applied. 
Considerations similar to those reported for the migration tests can be referred for 
KP1019 and RAPTA-T when cell invasion is studied: the first compound is active in a 
completely unselective manner, whereas RAPTA-T again displays its preferences to inhibit 
the behaviour of the highly invasive MDA-MB-231 cells. The selectivity showed by RAPTA-
T in the migration and invasion tests is similar to that demonstrated by NAMI-A when 
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applied in the same series of tests (Callerio Foundation, confidential data). All the other 
complexes are completely devoid of effects. 
The invasive capacity of cancer cells relies also on the production and secretion of 
proteases digesting the extracellular matrix. The activity of gelatinases MMP-2 and MMP-9, 
as detected by zymography, is moderately but selectively inhibited by KP418 and by RAPTA-
T on the invasive cells, and by RM175 and AFAP51 on the non tumorigenic HBL-100; on the 
contrary KP1019 inhibits gelatinases coming from both cell lines. The strong effect showed 
by KP1019 in these last three experimental models can be related with its cytotoxicity, 
evidenced by an MTT test performed on cells subjected to experimental conditions, 
corresponding to those used for the migration and invasion tests. KP1019 looses its in vitro 
cytotoxicity if it is used at 10-5 and 10-6 M and, correspondingly, also the inhibition of 
migration and invasion, disappears in these conditions further stressing the lack of selectivity 
of KP1019. The tumour cell growth inhibition by KP1019, detected in the experiments of the 
present work, is in line with several works that have largely investigated the induction of 
apoptosis, mediated by the mitochondrial pathway, following KP1019 treatment (Kapitza et 
al, 2005; Kapitza et al, 2005 a). 
The re-adhesion to a new growth substrate is the last step of the metastatic progression 
taken into consideration in this model, and it represents the adhesion of the metastatic cell to a 
distant organ after surviving the stresses of the bloodstream and the attack from the immune 
system (Steeg, 2006; Dollé et al, 2006). In general, the tested compounds demonstrate an 
activity not particularly relevant in this test, neither analyzing the results on the basis of the 
cell line treated, nor in relation to the substrate used for cell growth. The only exception is 
represented by RAPTA-T that re-confirms its selectivity towards the highly metastatic cells, 
whereas it does not show, in this experiment, a substrate specificity, strongly reducing the re-
adhesion to all the substrates belonging to the extracellular matrix, but also to poly-L-lysine, 
on which cells adhere by electrostatic interactions only (Elbert et al, 1998). 
The results obtained in the in vitro series of experiments, although significant and 
indicative of the potential anti-metastatic activity of the compounds, need the evaluation of 
the in vivo activity. The data of activity of the same drugs in a model of solid metastasizing 
tumour, on primary tumour and on the lung metastases growth, reflect some of the behaviours 
emerged in the in vitro screening. KP1019 inhibits lung metastases, likely as a consequence of 
the reduced growth of the primary tumour, thus reflecting the cytotoxicity that influenced its 
strong effects in many of the in vitro tests. For RM175 there is not a clear correlation between 
in vitro and in vivo experiments, pheraps because its anti-metastatic activity could be ascribed 
only in part to a selective inhibition of the metastatic steps considered in the proposed model. 
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RM175 reduces the tumour at the primary site of growth and, correspondingly, lung 
metastases, at both dosages used. In our in vitro model RM175 does not exhibit a relevant 
cytotoxic effect, in contrast to literature data that compare its cytotoxic potency to that of 
carboplatin (Aird et al, 2002). This discrepancy can be explained by an intrinsic resistance of 
the MDA-MB-231 cells, but it should not be forgotten also the possible influence of the 
treatment schedule. In fact, in this in vitro model, the cells were exposed to the compounds for 
1h, a time that might not be sufficient for RM175 to induce the death of the treated cells. On 
the contrary, in vivo, the treatment was given for four or six consecutive days, a condition 
favouring the appearance of cytotoxic effects and of their consequences on tumour and 
metastases development. The other heterocyclic compound, KP418, evaluated in the Lewis 
lung carcinoma model (Zorzet et al, 2000), induced effects weaker than those of its parent 
KP1019, similarly to what found in vitro tests. AFAP51 is completely devoid of anti-tumour 
or anti-metastasis action, reflecting its anonymous in vitro activity; this lack of efficacy might 
be related to the relative inertness conferred to the compound by the osmium metal centre. In 
fact, AFAP51 undergoes hydrolysis ca 40 times more slowly than RM175 (Peacock et al, 
2006), and in parallel it is inactive towards the A2780 ovarian cancer cells, and also the rate 
and the extent of the reaction with nucleobases, such as 9-ethylguanine, were less pronounced 
than those of RM175 (Peacock et al, 2006). It should be clear that the activity of KP1019 and 
of RM175 is far to be unappreciable, considering that both compounds are able to cause the 
total lack of detectable metastases in 2 out of 11, and in 4 out of 10 treated animals, 
respectively. Nevertheless their effect are far from being selective, and it does not match the 
features required for a “true” anti-metastatic drug, mainly summarized by the capacity to 
selectively interfere with metastasis formation and growth with marginal or null effect on 
primary tumour growth. Such characteristic seems to belong to RAPTA-T, that interferes with 
the growth of lung metastasis, despite a negligible reduction of the primary tumour growth, a 
behaviour repeatedly shown by the reference compound NAMI-A (Sava et al, 1998; Sava et 
al, 1999; Sava et al, 2003). Moreover, the anti-metastatic activity displayed in vivo by 
RAPTA-T might be related to its in vitro activity, showing a preference for influencing the 
behaviour of the highly invasive cells. Besides a cell line-dependence, the in vitro activity of 
RAPTA-T is particularly relevant in the detachment and adhesion assays, both requiring the 
interaction of the tumour cells with ECM components, suggesting the importance of the 
tumour cell-extracellular matrix interactions in the mechanism of action of RAPTA-T, and 
likely the involvement of cell surface molecules in its activity. Additionally, the effects found 
in the detachment, re-adhesion and migration tests seem to be related with a common effect of 
the compound, consisting in the stiffening of the cell body, that translates into the loss of the 
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plasticity required for the processes of cell detachment, migration and re-adhesion. This 
hypothesis is, in part, confirmed by a light microscopy analysis, in which RAPTA-T treatment 
induces an evident elongation and spreading of cell body in MDA-MB-231 cells only. This 
preliminary analysis was followed by an in depth study of the actin cytoskeleton and of focal 
contacts in MDA-MB-231 and HBL-100 cells treated with different concentrations of 
RAPTA-T. Again, it emerges that the metal compound acts mainly on the highly invasive cell 
line. The concentration of 10-4 M seems to be the most effective to induce stress fibres and 
focal contacts formation in MDA-MB-231 cells grown on fibronectin and on collagen IV, but 
to a lesser extent also on poly-L-lysine. This observation could support the hypothesis, 
anticipated before, of the loss of cellular plasticity, that hampers the re-adhesion of the treated 
cells. 
The role of cytoskeleton remodelling in the cell migration, a cyclic process of cell 
detachment and cell re-adhesion, is a crucial event for the metastatic processes. At molecular 
level, the formation of focal contacts and of stress fibres relies on the activity of RhoGTPases 
(Jaffe and Hall, 2005). Salvicine, a compound recently described for its anti-metastatic 
activity, has been proven to exert its pharmacological activity through a Rho-dependent 
pathway (Lang et al, 2005), thus highlighting the central role played by RhoGTPases in the 
metastatic process (Gomez et al, 2005; Vega and Ridley, 2008). In the presented model 
RAPTA-T treatment is able to revert the activity of an inhibitor of the RhoGTPases RhoA, 
RhoB, and RhoC, in the detachment assay. This test allows to observe an interesting 
correlation between the effects of the inhibitor and those of RAPTA-T. The treatment of both 
cell lines seeded on poly-L-lysine, and of the HBL-100 cells seeded on fibronectin with the 
inhibitor, does not reduce or reduces only weakly the amount of cells still remaining adherent 
after their exposure to trypsin. In these conditions, RAPTA-T treatment is not able to increase 
cell resistance to detachment. On the contrary, on MDA-MB-231 cells sown on collagen IV 
and on fibronectin, and on HBL-100 cells on collagen IV, the treatment with the Rho inhibitor 
decreases the number of adherent cells, and RAPTA-T shows a strong and dose dependent 
effect in the inhibition of cell detachment, when used on cells not exposed to the Rho 
inhibitor, as already evidenced in the tests reported in the first part of this work, but it also 
counteracts the effect of the inhibitor starting from the concentration 10-5M, and more 
strongly at 10-4 M. This fact suggests that probably there is a relation between the state of 
activation of the RhoGTPases and the capability of RAPTA-T to cause its effects on cell 
resistance to detachment. In fact the treatment with the inhibitor decreases adherent cells and 
RAPTA-T increases adherent cells. The treatment with an inhibitor, that selectively 
inactivates the GTPases RhoA, RhoB and RhoC, inhibits the formation of actin stress fibres, 
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as detected in confocal microscopy studies; on this event, treatment with RAPTA-T has, in 
generally, an opposite effect, promoting stress fibres formation. When RAPTA-T treatment is 
applied on cells pre-treated with the Rho inhibitor, the metal compound has only a weak 
efficacy in restoring cell capability to organize actin filaments. This fact suggests that 
RAPTA-T counteracts the activity of the inhibitor, with a mechanism unrelated to the 
restoration of actin filaments, but probably related to the increase of cellular spread. In fact, 
looking at cellular morphology, the cells treated with the Rho inhibitor lose the spread 
morphology, that might be, in some cases, restored after RAPTA-T treatment at the highest 
concentration of 10-4 M. Among the RhoGTPases, RhoA possesses a crucial role in the 
processes of adhesion (formation of focal contacts) and cell motility (remodelling of actin 
cytoskeleton) (Jaffe and Hall, 2005). Also Salvicine seems to have effects related with the 
state of activation of this RhoGTPase (Lang et al, 2004; Zhou et al, 2008). Despite all these 
evidences, RAPTA-T treatment does not show any strong effect in the activation state of 
RhoA. Noteworthy, on the non tumorigenic cell line, RAPTA-T treatment, at all the 
concentration tested and virtually on all the substrates, causes a general reduction of the 
activation of RhoA. Moreover, on the HBL-100 cells grown on fibronectin and on collagen 
IV, the effect of a specific RhoA activator, i.e. Cytochalasin D, is not as strong as expected 
(Ren et al, 1999), suggesting that on this cell line the activation of RhoA needs different 
conditions. On the highly invasive cell line, RAPTA-T treatment has controversial effects, 
that can not be related with the effects detected in the immunofluorescence analysis. 
The activation of the RhoGTPases is dependent also on their prenylation and 
localization at plasmatic membrane level (Dovas and Couchman, 2005), for this reason the 
analysis of the activation state of RhoA alone, does not allow to exclude an influence of 
RAPTA-T on other activation related events. Moreover, all the members of the RhoGTPase 
family (RhoA, B, C, Rac and Cdc42) are involved in cell motility and adhesion, it is to say 
that other molecules of the same group might be implicated in the RAPTA-T effects, and the 
analysis of RhoA only does not settle the relations between RAPTA-T and RhoGTPases. 
The uptake of a drug is a crucial aspect in its activity and it is directly related with 
phenomena of multi drug resistance caused by an increased extrusion of the drug (Ravna and 
Sager, 2009). Regarding RAPTA-T some interesting features have been observed in relation 
with its cellular uptake. In general, RAPTA-T uptake is more relevant in the highly invasive 
cell line, than in the non tumorigenic one: this effect is dose dependent, and time of exposure 
dependent. The maximal differential uptake between the two cell lines is detected at the 
highest concentration used and after 1hour of cell exposure to the drug. Of particular interest 
is the observation that, when the cells are seeded on ECM components, the uptake of 
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RAPTA-T by the highly invasive cell line, and the difference with that of the non-tumorigenic 
one, is higher respect to what observed on poly-L-lysine. These results allow to relate the 
selective activity of RAPTA-T on the highly invasive cell line, grown on ECM components, 
with a higher association of the drug to the cells; a similar comment does not adapt to 
experiments performed with HBL-100 cells. 
In the last years, studies related with the search of targets for the anti-tumour 
chemotherapy are focussing on the central role of the tumour microenvironment, considering 
both non-tumour cells and extracellular matrix (Hanna et al, 2009; Joyce, 2005). On these 
bases, it is of particular interest the fact that RAPTA-T is able to bind mainly the substrates 
belonging to ECM, like fibronectin and collagen IV, and less the unspecific poly-L-lysine. 
The evaluation of a possible effect of the compound bound to the substrates, on cellular 
adhesion, showed a more pronounced action (although not significant) on cells adhering on 
ECM substrates. In particular the highly invasive cell line adheres with more efficacy on 
RAPTA-T pre-treated fibronectin and collagen IV, while the non tumorigenic one on collagen 
IV only. This interesting and recurrent relation between the mechanism of action of RAPTA-
T and the cellular growth substrates has led to an NMR analysis of the products derived from 
the incubation of a RAPTA-T with the single substrates. The interesting results obtained 
showed that only when RAPTA-T is incubated with collagen IV there is the formation of 
interaction products. The different behaviour of RAPTA-T in the presence of collagen IV 
observed with NMR analyse, and the recurrence of a different behaviour in functional tests of 
the cells treated on this substrate (cellular spread, time course of cellular uptake…), 
underlines the central role of cell-ECM interactions in RAPTA-T mechanism of action. The 
importance of the integrin receptors in the interactions of the cell with the ECM components 
(Berrier and Yamada, 2007) and their role in cancer progression (Desgrossellier et al, 2010), 
suggested to investigate the possible interaction of RAPTA-T with integrins, particularly with 
α1β1, the natural ligand for collagen IV. No direct interaction between RAPTA-T and α1β1 
integrin was detected, nor the ruthenium compound is able to interfere in the binding of this 
integrin with its natural ligand collagen IV, as observed both at cellular and at molecular 
levels. However, RAPTA-T is able to act on cells immediately after their adhesion, when only 
the first adhesion molecules are engaged, decreasing their capability to detach, mainly when 
they are seeded on collagen IV. For MDA-MB-231 this can be ascribed to the kinetic of 
uptake observed on this substrate: in fact, RAPTA-T seems to associate faster to MDA-MB-
231 cells grown on collagen IV in comparison with the same cells grown on fibronectin or on 
poly-L-lysine. This evidence allow us to hypothesize an interference of RAPTA-T with 
integrinic receptors at different levels. The effect on cells immediately after the adhesion on 
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the substrate, that is to say mainly adherent with integrinic receptors, could be due to the fact 
that RAPTA-T, very rapidly, interacts mainly with integrins in the form already bound with 
the substrate, while it needs a longer time to bind to a free integrin. 
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6 Conclusions 
This project had two main goals: to set up a model of metastatic progression in vitro, 
and to unravel the determinant ligands conferring anti-metastatic activity to a metal-based 
compound. For this purpose, some representative complexes have been chosen: two 
heterocyclic compounds KP418, HIm[Ru(III)Cl4(Im)2], and KP1019, HInd[Ru(III)Cl4(Ind)2], 
presenting a different N-donor ligand, and three organometallic compounds, RM175, [(η6-
biphenyl)Ru(II)Cl-(ethylendiamine)]PF6, its osmium congener AFAP51, [(η6-
biphenyl)Os(II)Cl(ethylene-diamine)]BF4, and RAPTA-T, [RuCl2(η6-toluene)PTA], carrying 
a PTA ligand instead of ethylendiamine. The effects of the compounds on the interference 
with some steps of the metastatic progression are evaluated with appropriate in vitro tests, 
comparing the behaviour of the human MDA-MB-231 highly invasive breast cancer cells to 
that of human HBL-100 non tumorigenic mammary epithelial cells. 
From the screening, two compounds, KP1019 and RM175, emerged for their 
unselective anti-tumour activity in vivo; KP418 and AFAP51 display mild or no effects both 
in vitro and in vivo. The organometallic compound RAPTA-T showed selectively in vitro 
towards the highly invasive cell line, accompanied by a selective inhibition of metastasis 
development in vivo. 
These findings allow us to draw some conclusions. First of all, the metal centre of the 
drug is crucial for the biological activity of the compounds: it is completely lost when 
ruthenium is replaced with osmium. Regarding the other chemical features, the analysis of the 
structure-activity relationships gives no clear-cut conclusions, and it is impossible to say what 
are the minimal essential characteristics a ruthenium-based drug should have to act as anti-
tumour or anti-metastatic molecule. In fact, the effects of KP1019 and of RM175, although 
appreciable, are far from being selective and the inhibition of metastasis appears as a 
consequence of the reduction of primary tumour growth. From a chemical point of view the 
two compounds exhibit many differences: KP1019 is an heterocyclic compound, whereas 
RM175 is organometallic; KP1019 carries ruthenium at +3 oxidation state, whereas in 
RM175, ruthenium is at +2 oxidation state; also, the ligands in the coordination sphere are 
different, being indazoles in KP1019, and arene and ethylediamine in RM175. Moreover, 
KP1019 has a chemical structure more close to that of the selective anti-metastatic ruthenium 
drug NAMI-A, than that of RAPTA-T, the only compound among the five tested here, to have 
a discrete selectivity against secondary tumours. 
The correspondence between in vitro activity and in vivo anti-metastatic efficacy is 
good for KP1019 and RAPTA-T. The first acts on all the in vitro tests because of its 
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cytotoxicity, and correspondingly, in vivo it shows anti-tumour and anti-metastatic actions 
possibly driven by the same mechanism(s). The anti-metastatic activity displayed in vivo by 
RAPTA-T might also be related with its in vitro behaviour on tumour cells, mainly consisting 
in a pronounced influence of the behaviour of the highly invasive cells. Moreover, the in vitro 
tests most significant for the prediction of the in vivo efficacy seem to be those mimicking the 
detachment from the primary tumour, the invasion and the re-adhesion to a new growth 
substrate. This conclusion is supported by the fact that NAMI-A also is able to interfere with 
these types of experiments, selectively acting on the highly metastatic cells. This 
consideration permits us to validate the use of these tests to help the selection of molecules 
endowed with anti-metastatic activity. 
The in vitro activity of RAPTA-T, particularly relevant in the detachment and adhesion 
assays, both requiring the interaction of the tumour cells with ECM components, suggests the 
importance of the tumour cell-extracellular matrix interactions in the mechanism of action of 
RAPTA-T, and likely the involvement of cell surface molecules in its activity. In particular 
RAPTA-T induces a cytoskeleton remodelling, mainly through the formation of stress fibres, 
that causes a stiffening of the cell body. These effects, selectively identified in the highly 
invasive MDA-MB-231 cells, can be related to the higher ruthenium uptake, detected in this 
cell line. Also molecules of the RhoGTPases family are affected by RAPTA-T treatment, as 
indicated by the reversal of their effects on cell behaviour by the ruthenium compound. These 
molecular events might stem from the cell surface and involve integrin adhesion molecules, as 
suggested by the role of ECM components in the functional tests and by the preference of 
RAPTA-T to bind them, above all, collagen IV, with which RAPTA-T interacts chemically as 
confirmed by an NMR analysis. The effect of RAPTA-T on cells immediately after the 
adhesion on the substrate, i.e. mainly adherent with integrinic receptors, suggests that 
RAPTA-T interacts mainly with integrins in the form already bound with the substrate. 
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